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  Summary 
1. Summary 
 
The most prominent neurodegenerative disorder associated with dopaminergic cell 
loss is Parkinson’s disease (PD). The main hallmark of PD is the progressive loss of 
substantia nigra neurons. The neuronal loss results in severe dopamine depletion in 
the striatum, responsible for the motor symptoms associated with PD, especially 
tremor, rigidity and bradykinesia. Although the pathological changes that characterize 
the disease are well documented, the mechanism responsible for the death of 
dopaminergic neurons remains to be unraveled. However, studies showed that 
oxidative stress is of major importance in the etiology of the disease. In order to 
efficiently respond to hazardous conditions, cellular stress sensors are required, like 
the nucleolus, which responds to cellular stress by stabilizing the transcription factor 
p53. Therefore, the aim of the present study was the analysis of the importance of 
the nucleolar function in the oxidative stress response in dopaminergic neurons and 
its implications in the etiology of PD.  
The main function of the nucleolus, a sub-organelle of the cell nucleus, is the 
production and assembly of ribosome components. Nucleoli are made of protein and 
ribosomal DNA (rDNA) sequences of chromosomes, which serves as the template 
for transcription of the ribosomal RNA (rRNA) for inclusion in new ribosomes. 
Following increased oxidative stress in dopaminergic neurons by 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridin (MPTP) treatment, impairment of nucleolar structure and 
reduced nucleolar activity (RNA polymerase I) was discernible. The key player in the 
regulation of rDNA transcription is the transcription initiation factor IA (TIF-IA), which 
is responsible for the adjustment of cell biosynthetic activities to environmental 
conditions. In order to elucidate the role of the nucleolus within dopaminergic 
neurons, the Cre/loxP recombination system was used to generate mouse mutants, 
in which the function of the nucleolus was artificially disrupted by the ablation of TIF-
IA in dopaminergic neurons (TIF-IADATCre). The impairment of nucleolar function leads 
to progressive loss of dopaminergic neurons, reduction of the striatal dopamine 
content and severely impaired locomotor performance, closely mimicking the 
symptoms in PD. Remarkably, nucleolar disruption causes mitochondrial impairment 
before structural changes in dopaminergic neurons or their projections to the striatum 
were observed.  
To assess in more detail how nucleolar disruption affects mitochondrial function, 
mutant mice expressing an inducible Cre recombinase have been generated, 
allowing the spatio-temporal control of the Cre-mediated TIF-IA ablation. By means 
of Cre reporter mice reliable expression of the Cre recombinase was ensured 
specifically in dopaminergic neurons and very low background activity of the 
transgene in absence of the ligand was detected. Activation of the Cre-mediated TIF-
IA ablation in 2 months old animals (TIF-IADATCreERT2) leads to perturbation of 
nucleolar function followed by upregulation of p53, accompanied with mitochondrial 
dysfunction, leading to increased oxidative stress  and finally to progressive loss of 
dopaminergic neurons. Treatment of TIF-IADATCreERT2 and control mice with MPTP 
showed that an intact nucleolus is crucial for the balancing of the oxidative insult. The 
study was complemented by the analysis of PD samples in which increased 
nucleolar disruption could be observed. The results show the importance of nucleolar 
activity in the oxidative stress response in dopaminergic neurons, reveal a 
relationship between nucleolar and mitochondrial function, providing a new animal 
model for PD research and offer a new perspective on the neurodegenerative 
process of PD.  
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  Zusammenfassung 
1.1 Zusammenfassung 
Die bekannteste neurodegenerative Krankheit, welche mit dem Verlust von 
dopaminergen Neuronen zusammenhängt, ist die Parkinsonsche Erkrankung. Das 
Hauptmerkmal dieser Krankheit ist der langsam fortschreitende Verlust der 
dopaminergen Neuronen.  Dieser Verlust führt zu einer Verminderung der 
Dopaminkonzentration im Striatum, welche verantwortlich ist für motorische 
Störungen wie Muskelstarre, Muskelzittern und Bewegungsarmut. Obwohl die 
pathologischen Veränderungen sehr genau beschrieben sind, ist der 
zugrundeliegende Mechanismus nicht bekannt. Jedoch haben Studien gezeigt, dass 
erhöhter oxidativer Stress in dopaminergen Neuronen die Schlüsselrolle bei der 
Entstehung der Parkinsonschen Krankheit einnimmt. Zellen registrieren diesen 
Stress mit Hilfe spezifischer Sensoren wie bspw. des Nukleolus,  welcher auf 
wachsenden oxidativen Stress mit der Stabilisierung des Transkriptionsfaktor p53 
reagiert. Das Ziel dieser Arbeit ist, die Funktion des Nukleolus in dopaminergen 
Neuronen bei der oxidativen Stress-Antwort zu ermitteln, sowie dessen Rolle bei der 
Parkinsonschen Erkrankung.  
Durch das Nervengift 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) ausgelöste 
Erhöhung des oxidativen Stress, führte zu einer Beeinträchtigung der nucleolären 
Struktur sowie zu einer starken Reduktion der Transkriptionsrate der ribosomalen 
DNA. Es wurde gezeigt, dass die Regulation der rDNA-Transkription hauptsächlich 
durch den Transkriptions-Initiations-Faktor-IA (TIF-IA) erfolgt, welcher für die 
Abstimmung der biosynthetischen Aktivität der Zelle auf die jeweiligen 
Umgebungsbedingungen verantwortlich ist. Um die Funktionen des Nukleolus dabei 
näher untersuchen zu können, wurden Mausmutanten mit Hilfe des Cre/loxP 
Rekombinationssystems erzeugt (TIF-IADATCre), bei denen die Funktion des Nukleolus 
durch die Inaktivierung des TIF-IA Gens in dopaminergen Neuronen beeinträchtigt 
wurde. Diese Mutation führte zu einem langsamen Absterben der dopaminergen 
Neurone, reduziertem Dopamingehalt im Striatum und einer daraus resultierenden 
beeinträchtigten Motorik, welche die Symptome der Parkinsonschen Erkrankung 
widerspiegelt. 
Bemerkenswerterweise führt der Verlust von nukleolärer Funktion zu einer direkten 
Beeinträchtigung der mitochondrialen Aktivität, weit früher als die ersten strukturellen 
Veränderungen sichtbar werden. Um diese Sachlage näher analysieren zu können, 
wurden Mausmutanten, in denen zu einem festgelegten Zeitpunkt die Inaktivierung 
des TIF-IA Gens erfolgt, hergestellt (TIF-IADATCreERT2). Unter Zuhilfenahme einer Cre 
Reporter Mauslinie wurde die hohe Spezifität der Expression des Transgenes 
(DATCreERT2), sowie dessen geringe Hintergrundaktivität nachgewiesen.  Die 
Aktivierung des Ablationssystems führt zu einer Beeinträchtigung der nukleolären 
Funktionen, dann zu p53 Hochregulation, gefolgt von mitochondrialer 
Beeinträchtigung und steigendem oxidativen Stress, welcher schließlich zu einem 
progressiven Verlust von dopaminergen Neuronen führte. Ferner wurde durch TIF-
IADATCreERT2 und Kontrollmäuse, welche mit MPTP zwei Wochen nach Aktivierung des 
Ablationssystems behandelt wurden, gezeigt, dass zur Kompensation von oxidativem 
Stress ein intakter Nukleolus notwendig ist. Des Weiteren ergab die Analyse von 
Gewebe von Parkinsonpatienten eine deutlich geringere Anzahl an intakten Nukleoli 
in dopaminergen Neuronen im direkten Vergleich mit Kontrollgewebe. Die 
Ergebnisse, welche hier präsentiert werden, zeigen die Bedeutung nukleolärer 
Aktivität bei der oxidativen Stress-Antwort in dopaminergen Neuronen, beschreiben 
eine Interaktion zwischen dem Nukleolus und dem Mitochondrium und liefern neue 
Mausmodelle bzw. Denkansätze für die Erforschung und das Verständnis der 
Parkinsonschen Erkrankung. 
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2. Introduction 
 
2.1 Neural development 
The development of the nervous system starts at a relatively late stage during 
embryogenesis after the three main cellular layers endoderm, mesoderm and 
ectoderm have been developed. The ectoderm develops into the major 
tissues of central and peripheral nervous systems. After the process of 
neurulation, in which the neural plate folds into a tubular structure, called 
neural tube, the caudal region of the neural tube gives rise to the spinal cord 
while the rostral part becomes the brain. Through this early stage, rapidly 
proliferating cells form three brain vesicles: the forebrain (prosencephalon), 
the midbrain (mesencephalon) and the hindbrain (rhombencephalon). The 
differentiation of cells in the nervous system is the consequence of a complex 
program that directs the expression of specific genes in individual cells. In the 
last phases of this program the development of dopaminergic neurons occurs 
(Principles of neural science 4th edition; Fundamental Neuroscience 2nd 
edition; Molecular biology of the cell 3rd edition).  
 
2.2 Dopaminergic neurons 
Dopaminergic neurons are an anatomically and functionally heterogeneous 
group of cells, localized in the forebrain, midbrain and the olfactory bulb. The 
most prominent dopaminergic cell group resides in the ventral part of 
mesencephalon, which contains approximately 90% of the total number of 
brain dopaminergic cells. The mesencephalic dopaminergic system has been 
subdivided into several systems (Fig. 1). Prominent among is the nigrostriatal 
system, which originates in the zona compacta of the substantia nigra (Fig. 1 
– light blue) and extends its fibers in the caudate-putamen (also known as the 
dorsal striatum). The nigrostriatal pathway plays an essential role in the 
control of voluntary motor movement. More medial to this pathway are the 
mesolimbic and mesocortical dopaminergic systems, which arise from 
dopaminergic cells residing in the ventral tegmental area (VTA) (Fig. 1 - blue). 
These systems are involved in emotion-based behavior including motivation 
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and reward. The cells of the VTA project most prominently into the nucleus 
accumbens, olfactory tubercle but also innervate the septum, amygdala and 
hippocampus. This subset of the projections is known as the mesolimbic 
dopaminergic system. Cells of the medial VTA project to the prefrontal, 
cingulate and perirhinal cortex. This pathway is known as the mesocortical 
dopaminergic system. There is considerable overlap between the VTA cells 
that project to these various targets. Because of the overlap between the 
mesocortical and mesolimbic dopaminergic neurons, the two systems are 
often collectively referred to as the mesocorticolimbic system.  
The tuberoinfundibular pathway transmits dopamine from the hypothalamus to 
the pituitary gland (Fig. 1 – dark blue). This pathway influences the secretion 
of certain hormones, including prolactin (Principles of neural science 4th 
edition; Wise, 2004). 
 
 
 
Figure 1: The different dopaminergic pathways in human brain  
       (Adapted from BrainNet) 
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2.3 Dopamine and associated cellular pathologies 
Considerable differences exist in the numbers of dopaminergic cell bodies in 
various mammals ranging from about 30.000 in the mouse (total number: 
7,5x107 neurons), or 590.000 in humans (total number: 1011 neurons) 
(German and Manaye, 1993). Although dopaminergic neurons correspond to 
less than 1% of the total number of brain neurons, they nevertheless play an 
important role in regulating numerous aspects of basic brain function, like 
motor behavior, motivation and working memory. Hence, the regulation of 
dopamine plays a crucial role in both mental and physical health (Wise, 2004). 
In 1952, Arvid Carlsson and colleagues discovered dopamine. They found 
that dopamine is not just a precursor of norepinephrine and epinephrine but 
acts as a neurotransmitter as well (Benes, 2001). In the brain, dopamine 
functions as a neurotransmitter, activating five different types of dopamine 
receptors (D1-D5), whereas dopamine released by the hypothalamus acts as 
neurohormone, by inhibition of the prolactin release from the anterior lobe of 
the pituitary. As a member of the catecholamine family (includes substances 
consisting of catechol: aromatic structure with two hydroxyl groups), dopamine 
is a precursor to norepinephrine and epinephrine in the biosynthetic pathways 
for these neurotransmitters.  
Dopamine is biosynthesized in the body (mainly by nervous tissue and the 
medulla of the adrenal glands) first by the hydration of the amino acid L-
tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine) via the enzyme tyrosine 
hydroxylase followed by the decarboxylation of L-DOPA by aromatic L-amino 
acid decarboxylase (Fig. 2). Dopamine is thought to be capable of generating 
toxic reactive oxygen species (ROS) via both its enzymatic and non-
enzymatic catabolism (Halliwell, 1992). Specifically, dopamine oxidation can 
occur either spontaneously in the presence of transition metal ions or via an 
enzyme-catalyzed reaction involving the monoamine oxidase (MAO). 
Oxidation of dopamine via MAO generates a spectrum of toxic species 
including H2O2, oxygen radicals, semiquinones, and quinones (Graham, et al., 
1978). At the same time dopaminergic neurons are known to be particularly 
prone to oxidative stress most likely due to their high rate of oxygen 
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metabolism, low levels of antioxidants and high iron content (Dauer and 
Przedborski, 2003).  
 
 
 
 
 
       Figure 2: Biosynthesis of dopamine  
            (Adapted from Biochemistry 5th edition)   
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2.4 Parkinson’s disease  
The most prominent neurodegenerative disorders associated with 
dopaminergic cell loss is Parkinson’s disease (PD). In PD, which was first 
described by James Parkinson in 1817, the loss of nigral neurons follows a 
specific pattern with the more susceptible area being located laterally in the 
ventral part of the substantia nigra (Parkinson, 2002). This results in severe 
dopamine depletion in the striatum, responsible for the motor symptoms 
associated with PD, especially bradykinesia (slowness of movement), tremor, 
rigidity and loss of postural control (Lang and Lozano, 1998b, Lang and 
Lozano, 1998a). Other less severe lesions, such as degeneration of the 
dopaminergic VTA, the noradrenergic locus coeruleus and the ascending 
cholinergic pathway from the Meynert basalis nucleus are also observed 
(Candy, et al., 1983). Additionally, dopaminergic cell loss can be associated 
with the presence of eosinophilic intraneuronal inclusions, called Lewy bodies, 
composing of alpha-synuclein, parkin and ubiquitin (Goldman, et al., 1983). 
Although the pathological changes and motor dysfunction that characterize 
the disease are well documented, the mechanism responsible for the death of 
dopaminergic neurons remains to be unraveled. Therefore, most of the 
current treatment for the disease is largely symptomatic. So far, the most 
commonly prescribed drug for PD is the DA precursor L-DOPA (Birkmayer 
and Hornykiewicz, 1961). It is used as treatment for PD patients to replace 
lost midbrain dopamine. Unfortunately, L-DOPA and other parkinsonian drugs 
are only able to alleviate the symptoms of the disease but not ongoing cell 
death and eventually become ineffective once enough dopaminergic neurons 
are lost. Moreover, many patients develop dyskinesia (abnormal involuntary 
movements) and motor fluctuations within a few years of L-DOPA treatment 
(Ahlskog and Muenter, 2001). L-DOPA-induced dyskinesia (LID) is the earliest 
and most common complication and is typically associated with an 
idiosyncratic mixture of chorea (abrupt movements that seem to flow from one 
body part to another) and dystonia (slow twisting movement) (Cenci, 2007).  
Therefore there has been resurgence in the use of surgical techniques such 
as pallidotomy and thalamotomy in which lesions are made in the patient's 
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globus pallidus or thalamus, respectively, which was used before L-DOPA 
was discovered, to treat PD (Kashihara, 2007). Unfortunately, surgical 
treatment is not effective in PD patients. New experimental methods including 
deep brain stimulation, where electrodes stimulate the thalamus and 
implantation of stem cells in the striatum are currently under investigation 
(Lindvall and Kokaia, 2006, Kern and Kumar, 2007). 
 
 
2.5 Molecular mechanism of PD 
The major breakthrough in elucidating the etiology of the disease resulted 
from the accidental discovery of 1-methyl-4-phenyl-1,2,3,6-terahydropyridine 
(MPTP). In 1976, a chemistry graduate student was hospitalized after 
exhibiting Parkinson-like symptoms. It was found that the cause of his 
condition was injection of MPTP, a product of an incorrect reaction while trying 
to prepare a synthetic opioid. After his death, a selective destruction of 
dopamine neurons in the SN was discovered (Parkinson’s disease 1st edition, 
S.A. Factor and W.J. Weiner). Due to the relatively selective degeneration of 
dopaminergic neurons MPTP-treatment of animals is the most commonly 
studied PD model (Przedborski and Vila, 2003) .  
MPTP itself is not toxic and as a lipophilic compound it can cross the blood-
brain barrier. Once inside the brain, MPTP is metabolized by glia cells into 1-
methyl-4-phenylpyridinium (MPP+) and via high-affinity uptake of the 
dopamine transporter MPP+ enters dopaminergic neurons. MPP+ is a toxic 
compound that interferes with complex I of the respiratory electron transport 
chain, causing the buildup of free radicals and molecules that contribute to cell 
destruction (Schober, 2004). So it is not surprising that studies have first 
focused on the three types of cellular dysfunction that may be important in the 
pathogenesis of PD: oxidative stress, mitochondrial respiration defect and 
abnormal protein aggregation. This situation changed in 1997 with the 
discovery that mutations in the gene for alpha-synuclein cause an inherited 
form of PD. In the following  years several additional PD-causing genes have 
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been identified including Parkin, Ubiquitin C-terminal hydrolase-L1 (UCH-L1), 
PTEN-induced kinase-1 (PINK1) and DJ-1 (PARK7) (Forman, et al., 2005).  
So far the relationship between the molecular pathways modified by these 
disease-associated genes and previous identified factors (like mitochondrial 
dysfunction) remains to be elucidated. Nevertheless it seems that oxidative 
stress is of major importance in the etiology of the disease (Vila and 
Przedborski, 2003, Moore, et al., 2005, Abou-Sleiman, et al., 2006, Lin and 
Beal, 2006). 
Certain neurotoxins (like MPTP, 6-OHDA, etc) are known to induce 
parkinsonism in humans (Dauer and Przedborski, 2003). The majority of these 
neurotoxins inhibit the respiratory chain in mitochondria, resulting in increased 
production of reactive oxygen species (ROS) like oxygen ions, free radicals or 
hydrogen peroxide, which may damage proteins, lipids and DNA, finally 
leading to cell death (Lotharius and Brundin, 2002). Consistent with 
mitochondrial damage and ROS accumulation playing a crucial role in PD, 
inherited forms of PD contain mutations in genes that protect dopaminergic 
neurons against oxidative stress, such as Parkin, DJ-1 and PTEN-induced 
kinase-1 (PINK1) (Abou-Sleiman, et al., 2006, Lin and Beal, 2006). Studies in 
Drosophila have revealed the role of DJ-1 in the anti-oxidative response and 
established that PINK1 and Parkin act in the same pathway to control 
mitochondrial physiology (Bier, 2006). These results point to a distinct 
molecular pathway involved in the demise of dopaminergic neurons in PD. 
In order to efficiently respond to hazardous conditions, cellular ROS sensors 
exist that monitor oxidative stress and regulate either the expression of 
antioxidant genes or genes that promote cell death (Storz, 2006). The 
nucleolus, traditionally regarded as the organelle of ribosome biosynthesis, 
has recently been implicated in sensing and responding to cellular stress by 
stabilizing the protein 53  (p53) (Rubbi and Milner, 2003, Mayer and Grummt, 
2005, Boisvert, et al., 2007, Kruhlak, et al., 2007). 
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2.6 The nucleolus: site of ribosomal RNA synthesis 
The nucleolus is a distinct sub-nuclear compartment that was first observed 
more than 200 years ago. It is roughly spherical and surrounded by a layer of 
condensed chromatin. Nucleoli assemble around the tandemly repeated 
ribosomal DNA gene clusters and 28S, 18S and 5.8S ribosomal RNAs 
(rRNAs) are transcribed as a single precursor (pre-RNA). Subsequently the 
precursors are processed and assembled with the 5S rRNA into ribosome 
subunits (Boisvert, et al., 2007). Although the nucleolus is primarily associated 
with ribosome biogenesis, several lines of evidence show that it has additional 
functions, like regulation of mitosis, cell-cycle progression, proliferation, and 
more recently many forms of stress response (Olson, et al., 2002).   
Mammalian cells contain 100 or more copies of tandemly repeated rRNA 
genes per haploid genome. These genes are transcribed with high efficiency 
to keep up with the cells metabolic activity and demand for ribosomes. 
Alterations in cell proliferation are accompanied by profound changes in the 
transcription rate of rRNA genes by RNA polymerase I (Pol I), responsible for 
the transcription of large rRNA genes. Thus, by responding to changes in the 
cellular environment, transcription by Pol I ultimately determines ribosome 
production and the potential for cell growth and proliferation or survival 
(Boisvert, et al., 2007).  
 
 
2.7 RNA polymerase I 
RNA polymerase I (Pol I) is a multimeric protein complex and its sole function 
is the transcription of genes encoding the large rRNAs (28S, 18S and 5,8S). 
Like RNA polymerase II and III it requires auxiliary factors that mediate 
promoter recognition, promote transcription elongation and facilitate 
transcription termination. RNA polymerase I needs at least four basal 
transcription initiation factors, upstream binding factor (UBF), the promoter 
selectively factors transcription initiation factor-IA (TIF-IA), transcription 
initiation factor-IB (TIF-IB) and transcription initiation factor-IC (TIF-IC) (Fig. 
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3). The key player in growth-dependent regulation of rDNA transcription is 
TIF-IA. A pre-initiation complex containing Pol I can be formed in the absence 
of TIF-IA, however formation of the first phosphodiester-bond of the RNA 
transcript requires the presence of TIF-IA. Following initiation, TIF-IA is 
released from the ternary complex and can associate with another pre-
initiation complex. The activity of TIF-IA is regulated by diverse extracellular 
signals, suggesting that this factor adapts Pol I transcription to cell growth 
(Schnapp, et al., 1990, Yamamoto, et al., 1996, Bodem, et al., 2000, Mayer 
and Grummt, 2005). 
 
 
 
Figure 3:  Scheme of the recruitment of the RNA polymerase I (Pol I) to 
the rDNA sequences. 
Dimers of the upstream binding factor (UBF) bind to the UBE. A pre-initiation 
complex is formed by binding to various transcription initiation factors, like 
TIF-IA and TIF-IB. Recruitment of RNA Polymerase I to that complex 
concludes the formation of a transcriptional complex.  
 
 
 
2.8 Transcription initiation factor I A (TIF-IA)  
TIF-IA was initially identified as ‘an activity’ that complements transcriptional 
inactive extracts obtained from quiescent mouse cells (Buttgereit, et al., 
1985). Interactions between TIF-IA with Pol I are affected by diverse 
regulatory pathways that link the cells biosynthetic activities to environmental 
conditions. For example, it has been shown that nutrients starvation, density 
areas and protein synthesis inhibitor lead to inactivation of TIF-IA 
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(Cavanaugh, et al., 2002, Yuan, et al., 2005). Another mode of transcriptional 
regulation is phosphorylation. Since TIF-IA possesses multiple 
phosphorylation sites. It was shown that signals affecting cell metabolism alter 
the phosphorylation pattern of TIF-IA, for example in density arrested, 
cycloheximide treated and amino-acid starved cells TIF-IA is 
hypophosphorylated and incapable of binding Pol I. (Zhao, et al., 2003). The 
importance of this particular factor became clear with the reports that 
inactivation of the TIF-IA gene (knockout) in mice resulted in prenatal lethality. 
In addition in mouse embryonic fibroblasts (MEFs) Cre-mediated depletion of 
TIF-IA leads to disruption of nucleoli, cell cycle arrest, upregulation of p53 and 
induction of apoptosis (Yuan, et al., 2005, Grewal, et al., 2007).  
Under normal conditions, murine double minute 2 protein (MDM2) maintains 
p53 at low levels through ubiquitination and degradation by proteasomes (Tao 
and Levine, 1999, Sugimoto, et al., 2003). Under a variety of stress conditions 
certain ribosomal proteins (Lohrum, et al., 2003) or proteins associated with 
preribosomes, such as nucleophosmin (NPM, B23)(Kurki, et al., 2004) interact 
with MDM2 protecting p53 from degradation. These findings indicate that 
nucleolar proteins may trigger cellular damage responses by interfering with 
p53 turnover (Vousden and Lane, 2007).  
The correlation between perturbation of nucleolar function, elevated levels of 
p53 and induction of cell suicide supports the view that the nucleolus is a 
stress sensor and regulates p53 activity (Yuan, et al., 2005). So far there is no 
evidence that link the nucleolar function and oxidative stress in dopaminergic 
neurons.  
 
 
2.9 Aim of this thesis 
Oxidative stress seems to be the major cause for the demise of dopaminergic 
neurons and therefore is one of the suspects intensively investigated among 
others that cause and/or promote PD. Aim of the present study was the 
analysis of the importance of the nucleolus in the oxidative stress response in 
dopaminergic neurons and its implications in the etiology of PD.  
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Therefore the ability of the nucleolus to react upon oxidative stress in 
dopaminergic neurons was evaluated. Monitoring nucleolar integrity and 
activity should reveal a mutual relationship between oxidative stress and 
nucleolar perturbation. To further evaluate the role of the nucleolus, mouse 
mutants in which the nucleolus is artificially disrupted by the ablation of TIF-IA 
in dopaminergic neurons were generated using the Cre/loxP recombination 
system. The additional generation of an inducible Cre-recombinase mouse 
line allowed a spatio-temporal regulation of nucleolar disruption and thereby 
enabling to analyze the sequence of events, happening upon nucleolar 
disruption in dopaminergic neurons, more precisely.  
The analysis was concluded by the examination of human cases of PD in 
order to determine the involvement of the nucleolus (and rDNA transcription) 
in the development and progression of PD.  
  Results 
   
  
3. Results: 
 
3.1 MPTP affects nucleolar integrity and function. 
The nucleolus has recently been implicated in sensing of and responding to 
cellular stress (Olson, et al., 2002, Rubbi and Milner, 2003, Michel, et al., 
2006). To test if the nucleolus possesses the ability to react upon oxidative 
stress in dopaminergic neurons, nucleolar integrity and activity was monitored 
after injection of MPTP, a selective dopaminergic neurotoxin that inhibits the 
mitochondrial respiratory chain, leading to impaired energy production and 
increased oxidative stress (Przedborski and Vila, 2003, Schober, 2004).  
In control mice, the nucleoli within dopaminergic neurons are clearly visible as 
distinct punctuate nucleolar structures as revealed by nucleophosmin (NPM) 
distribution (Fig. 4a). After treatment with MPTP, nucleolar structure starts to 
be perturbed and NPM is found throughout the nucleoplasm (Fig. 4b,c). In situ 
hybridization using a digoxygenin-labeled probe against the 5’-ETS (externally 
transcribed spacer) of pre-rRNA revealed a strong reduction of nucleolar 
transcriptional activity in the midbrain of mice treated with MPTP (Fig. 4e) 
compared to mice treated with physiological saline (Fig. 4d). No significant 
change of pre-rRNA synthesis was observed in areas of the brain that are not 
targeted by the toxin, e.g. the hippocampus (Fig. 4f,g). Quantification of the in 
situ hybridization signals in tyrosine hydroxylase (TH+) containing 
dopaminergic neurons revealed that one day after MPTP administration the 
synthesis of pre-rRNA is already decreased by ∼50% (Fig. 4h).  
The finding that MPTP treatment not only impaired mitochondrial function in 
dopaminergic neurons but also affected the structure and transcriptional 
activity of nucleoli, suggests a link between nucleolar and mitochondrial 
function in MPTP-induced parkinsonism. 
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Figure 4: Effect of MPTP treatment on nucleolar activities.  
(a,b) Detection of nucleolar integrity in dopaminergic neurons by 
immunohistochemistry using NPM (brown) and TH (green) antibodies in 2 months old 
mice injected with either MPTP or saline over 3 days and analyzed 1 day after the 
last MPTP injection. (c) Quantification of the nucleolar disruption in dopaminergic 
neurons of mice injected with MPTP or saline by counting TH+ neurons showing 
NPM nuclear translocation (n=5; **, p<0.01). (d-g) Effect of MPTP on 47S pre-rRNA 
synthesis in the midbrain (d,e) and hippocampus (f,g) of mice treated with NaCl (d,f) 
or with MPTP (e,g). In situ hybridizations using a riboprobe recognizing the 5´ETS of 
the 47S pre-rRNA (blue) and TH immunohistochemistry (brown) to identify 
dopaminergic neurons are shown. (h) Quantitative analysis of pre-rRNA signals, 
expressed as number of blue dots in dopaminergic neurons in mice treated with NaCl 
and MPTP, shows reduced pre-rRNA levels in MPTP treated mice (n=3; **, p<0.01). 
Scale bars: b, 15µm; g, 100µm. 
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3.2 Progressive loss of dopaminergic neurons by genetic ablation of 
TIF-IA. 
The decrease in Pol I transcription after MPTP-induced oxidative stress 
revealed a functional interrelationship between the nucleolus and 
mitochondria. To explore the consequence of perturbing this interrelationship 
nucleolar function was specifically ablated in dopaminergic neurons by Cre-
mediated excision (Fig. 5) of the essential Pol I-specific loxP flanked exon of 
transcription factor TIF-IA allele (TIF-IAfl), which has been shown to cause 
nucleolar perturbation (Yuan, et al., 2005). TIF-IAfl/fl mice were crossed with 
mice expressing the Cre recombinase under the control of the regulatory 
elements of the dopamine transporter gene (DATCre)(Parlato, et al., 2006).  
 
 
 
 
 
Figure 5: The Cre/loxP recombination system allows cell-type specific 
inactivation of a target gene 
To achieve cell-type specific gene inactivation using the Cre/loxP-recombination 
system, an essential part of a gene has to be flanked by loxP sequences, without 
affecting the expression of the gene. The cell-type/tissue-specific expression of the 
Cre recombinase under control of specific regulatory elements results in deletion of 
the part that is flanked and thereby the gene inactivation occurs exclusively in Cre-
expressing cells.  
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Until day 15, TIF-IAfl/fl; DATCre mutants (TIF-IADATCre) were indistinguishable 
from control littermates. Thereafter, they were smaller and weighed less and 
these differences progressed with age (Fig. 6a). 
After 4 weeks TIF-IADATCre mutants exhibited motor impairment, starting with 
slowness of movements, gait and posture disturbances and resting tremor 
resembling PD symptomatology. These locomotor abnormalities were 
associated with alterations in the number of dopaminergic neurons. At P0, the 
number of neurons, identified by immunohistochemistry (IHC) with TH 
antibodies, was similar in control and TIF-IADATCre mice, while at later stages 
dopaminergic neurons were progressively lost (Fig. 6b,c). Importantly, 
dopaminergic neurons in the substantia nigra (SN) (Fig. 6b) were more rapidly 
and strongly affected than those in the ventral tegmental area (VTA) (Fig. 6c), 
mimicking the differential vulnerability of these two subpopulations of 
dopaminergic neurons in PD.  
To prove that dopaminergic neurons are preferentially lost in the SN the 
expression of TH  (Fig. 6d,e), Cre recombinase (Fig. 6f,g) and p53 was 
monitored by immunohistochemical analysis (Fig. 6h,i). The dopaminergic 
neurons in the VTA also showed strong p53 upregulation (Fig. 6h,i), indicating 
that these neurons are less sensitive to the consequences of nucleolar 
perturbation. 
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Figure 6: Progressive loss of dopaminergic neurons in TIF-IADATCre mutant mice.  
(a) Weight curves show growth differences between control and TIF-IADATCre 
littermates starting at P15 (n=8). (b,c) Quantification of TH+ neurons at different 
postnatal stages (P0, P15, P40, P90) revealed that mutant and control mice did not 
show any significant differences in number of dopaminergic neurons at birth, 
whereas they are progressively lost at later stages. Substantia nigra (SN) neurons 
(b) are more susceptible to the loss of TIF-IA than ventral tegmental area (VTA) 
neurons (c) (n=5). (d-g) Immunohistochemistry with antibodies specific for TH (D,E) 
or Cre recombinase (f,g) shows the preferential loss of dopaminergic neurons within 
the SN in mutant mice (e,g) compared to control mice (d,f) at P30. A littermate 
mouse expressing the Cre is shown as control. (h,i) Remaining dopaminergic 
neurons in the mutant VTA show p53 overexpression (i) whereas p53 level in control 
mice appear undetectable (h). (*, p<0.05; **, p<0.01; ***, p<0.001). Scale bar: 
100μm, insert 50μm. 
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3.3 Loss of striatal dopamine in TIF-IADATCre mutants.  
Loss of dopaminergic neurons in PD patients impairs dopamine production, 
leading to alterations of the neural circuits that regulate movement (Lang and 
Lozano, 1998b). Likewise, TIF-IADATCre mutants show locomotor abnormalities 
and progressive loss of dopaminergic neurons in the ventral midbrain. At P7, 
i.e. before dopaminergic neurons were lost, TH immunoreactivity in the 
striatum in TIF-IADATCre mice was reduced (Fig. 7b) and was barely detectable 
at P15 (Fig. 7d). Moreover, there was a gradual loss of TH-staining intensities 
in striata of mutant mice (Fig. 7e). The expression of the dopamine D1 
receptor in dopaminoceptive neurons did not change in TIF-IADATCre mutants, 
which underscores the specificity of the targeted mutational approach (Fig. 7 
f-h). Therefore, the observed phenotype recapitulates the selective loss of SN 
neurons observed in PD.  
To test whether loss of dopaminergic neurons should decrease the striatal 
dopamine content, we analyzed dopamine levels by High Performance Liquid 
Chromatography (HPLC) and electrochemical detection. TIF-IADATCre mice 
showed a 95% reduction of dopamine levels at 5 weeks of age compared to 
control mice (n=5) (Fig. 8a).  
The reduced striatal dopamine transmission should lead to impaired 
locomotor activity in TIF-IADATCre mutants compared to control mice of the 
same age. To assess locomotor dysfunction, the accelerating rotarod assay 
was performed, recording the time spent by the mice on the accelerating 
wheel (Yoshida, et al., 2003). At 4 weeks of age, a ∼50% reduction in motor 
performance of mutant mice was observed compared to controls. This 
decrease reached a ∼65% decline at 8 weeks of age (Fig. 8b). Together, 
these results demonstrate that ablation of TIF-IA leads to progressive loss of 
dopaminergic neurons in the SN and VTA, reduction of the striatal dopamine 
content and severely impaired locomotor performance. 
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Figure 7: TIF-IADATCre mutants show progressive loss of TH immnoreactivity in 
striata.  
(a-d) Immunohistochemistry specific for TH performed at P7 and P15 in control (a,b) 
and TIF-IADATCre mutants (c,d).(e) Levels of TH immunoreactivity (TH-ir) in striata at 
P7, P15 and P30 were normalized to control littermates and plotted as a histogram 
(n=4) for each time point. (f-h) No effect on dopaminoceptive neurons in TIF-IADATCre 
mutants. Postsynaptic cells in the striatum visualized by dopamine D1 receptor 
immunohistochemistry on sections of TIF-IADATCre (g,i) and control mice (f,h) at 
different stages (P7, P30) remained unchanged. No differences are visible between 
mutants (g,f) and respective controls (f,h) at P7, P15 and P30. (h) Levels of D1 
receptor immunoreactivity (D1R-ir) in striata at P7, P15 and P30 were normalized to 
control littermates and plotted as a histogram (n=4) for each time point.  Scale bar: 
250µm. 
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Figure 8: Lack of striatal dopamine leads to impaired locomotor activity  
(a) At P40 the dopamine content in striata measured by HPLC-ED showed a 95% 
reduction in comparison to the control group (n=5). (b) Locomotor deficits of TIF-
IADATCre mice determined by the accelerating rotarod assay. At P30 mutants showed 
a locomotor deficit of 55% and at P60 of 76% compared to control mice (n=5; p<0,01; 
***, p<0,001).  
 
 
 
3.4 Rescue of TIF-IADATCre mutant mice by L-DOPA treatment. 
Given that the main neuropathological feature of PD is the progressive demise 
of dopaminergic neurons, therapies for PD enhancing synaptic dopamine 
transmission have been developed. Among these, the dopamine precursor L-
3,4-dihydroxyphenylalanine (L-DOPA) still occupies a preeminent place 
(Carlsson, et al., 1957, Birkmayer and Hornykiewicz, 1961). We asked 
whether this treatment for PD symptomatology would rescue TIF-IADATCre 
mutant mice from developing the symptoms described above and from death. 
To this end, L-DOPA (50mg/kg) was injected daily over 3 weeks in 7 weeks 
old mice that already show a rather severe phenotype (n=4). While mutants 
without treatment with L-DOPA did not gain weight and died early, mutant 
mice treated with L-DOPA gained weight, showed reduced behavior 
abnormalities and were rescued from death (Fig. 9a). Moreover, increased 
growth of TIF-IADATCre mice was achieved 6 weeks after continuous treatment 
by implanting subcutaneous pellets releasing a constant amount of L-DOPA 
(Fig. 9b). Together, these data demonstrate the responsiveness of TIF-
IADATCre mutants towards L-DOPA administration, recapitulating an important 
characteristic of PD. 
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age [days after birth] 
Figure 9: L-DOPA administration increases lifespan of TIF-IADATCre mice 
(a) Rescue of TIF-IADATCre mice by L-DOPA injection. Mutant mice (7 weeks-old) 
treated by daily injecting L-DOPA for 3 weeks gained weight similarly to control mice, 
while untreated mutant mice died without gaining weight despite supplementation 
with liquid food (n=4). (b) Longer treatment (60 days) was achieved by implantation 
of a pellet releasing a constant amount of L-DOPA subcutaneously. Mutants display 
weight gain independent of sex (n=5; ***, p<0.001).  
 
 
 
3.5 Reduced mitochondrial activity upon nucleolar impairment 
Given the crucial role of mitochondrial dysfunction in PD, most strikingly 
reflected in patients with mutations in DJ-1, PINK1, Parkin and in Drosophila 
mutants modeling the disease (Vila and Przedborski, 2003, Moore, et al., 
2005, Abou-Sleiman, et al., 2006, Lin and Beal, 2006, Moore, et al., 2006), we 
assessed whether interference with TIF-IA activity and nucleolar integrity will 
lead to impaired mitochondrial function. TIF-IADATCre embryos at E18.5 were 
used and nucleolar expression of TH as a marker for dopaminergic neurons, 
Cre as a marker for expression of the transgene and p53 serving as a marker 
for nucleolar perturbation upon TIF-IA loss were monitored. At E15.5 only a 
few dopaminergic neurons express a detectable amount of Cre recombinase 
(Fig. 10b) and display p53 upregulation (Fig. 10c). In embryos at E18.5 Cre 
recombinase was detectable (Fig. 10h) and almost all dopaminergic neurons 
display p53 upregulation (Fig. 10i) suggesting that loss of TIF-IA occurred. 
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Figure 10: Response of dopaminergic neurons to TIF-IA ablation during 
embryonic development. 
(a-f) Adjacent sagittal sections of control and TIF-IADATCre mutants at E15.5 stained 
with antibodies against TH, Cre and p53. (a,d) TH is used for the identification of 
dopaminergic neurons in the ventral mesencephalon. (b,e) Expression of Cre-
recombinase in the same area (b) associated with p53-overexpression in the TIF-
IADATCre mutants (c), but not in control (e,f). (g-l) At E18.5 more cells are affected by 
the mutation in comparison to control (j-l), as visualized by the overexpression of p53 
in the mutants (i). Scale bar 50µm, inserts 20µm. 
 
 
 
 23
  Results 
   
  
One of the most frequent causes of mitochondrial defects is reduced activity 
of the cytochrome c oxidase (COX), and so COX activity is used as a marker 
for impaired mitochondrial activity (Bender, et al., 2006, Ekstrand, et al., 
2007). Embryos at E18.5, where TIF-IA ablation clearly affected most 
dopaminergic neurons were analyzed. In control embryos NPM is localized 
within the nucleoli, whereas in TIF-IADATCre mutants NPM is distributed 
throughout the nucleoplasm (Fig. 11a,b) as a result of TIF-IA loss. The 
nucleolar perturbation is accompanied by strong reduction of COX activity in 
the ventral mesencephalic area (Fig. 11d) compared to control mice (Fig. 
11c), indicating that loss of TIF-IA function affects mitochondrial activity. 
Intriguingly, nucleolar disruption influences mitochondrial activity before 
structural changes in dopaminergic neurons or their projections to the striatum 
became visible.   
 
 
 
Figure 11: Mitochondrial impairment upon nucleolar disruption.  
(a,b) Double immunoflorescence with NPM/B23 (green) and TH (red) shows 
disruption of nucleoli in TIF-IADATCre mutants at E18.5 in dopaminergic neurons, while 
nucleoli of control mice appear normal. (c,d) Control mice display intact COX activity 
(brown), whereas in TIF-IADATCre mice respiratory chain deficient neurons show violet 
cytoplasmic staining due to lack of COX activity. Scale bars: a,b, 20μm; c,d, 75μm. 
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3.6 Generation of a mouse line expressing an inducible Cre-
recombinase exclusively in dopaminergic neurons  
In order to assess in more detail the sequence of events that link nucleolar 
with mitochondrial function and to avoid developmental defects due to TIF-IA 
depletion during embryogenesis, we intended to generate transgenic mice 
expressing an inducible Cre recombinase in dopaminergic neurons. To 
achieve inducible recombination of conditional alleles in dopaminergic 
neurons of the adult brain, a BAC-derived transgene expressing the CreERT2 
fusion protein under the control of the regulatory elements of the mouse DAT 
gene (DATCreERT2) was generated. The CreERT2 fusion protein consists of 
the Cre recombinase and a mutated ligand-binding domain (LBD) of the 
human estrogen receptor (ER) (Feil, et al., 1997, Indra, et al., 1999). The ER-
LBD contains a nuclear localization signal that is unmasked upon ligand 
binding. Two point mutations in the ER-LBD allow activation exclusively by the 
synthetic ligand tamoxifen. The unliganded form of the CreERT2 fusion protein 
resides in the cytoplasm and only upon tamoxifen binding it translocates into 
the nucleus and mediates site-specific recombination (Fig. 12). 
 
 
Figure 12:  Schema of the inducible Cre/loxP system  
The Cre/loxP-recombination system has been modified with the tamoxifen-inducible 
fusion protein consisting of the Cre recombinase and the mutated ligand binding 
domain (LBD) of the human estrogen receptor (CreERT2) to achieve ligand dependent 
Cre activity. The unliganded form of the CreERT2 fusion protein resides in the 
cytoplasm and upon tamoxifen binding it translocates into the nucleus and mediates 
site-specific recombination of the loxP-flanked DNA sequence.  
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A BAC clone was selected that harbored a genomic insert containing the DAT 
gene locus (42kb) with a 51kb 5’upstream and a 46kb 3’downstream region 
from the mouse genome project (www.ensembl.org). To obtain the 
DATCreERT2 transgene, the coding sequence for the CreERT2 fusion protein 
was inserted into the reading frame in the second exon of the DAT locus (Fig. 
13) by homologous recombination in bacteria (Lee, et al., 2001). The modified 
genomic insert was released by NotI digestion and then separated from the 
BAC backbone and using a gel filtration column. Finally it was introduced into 
the mouse germline by oocytes injection (Schedl, et al., 1993). 
 
 
Figure 13:  Insertion of the CreERT2 cassette into a genomic BAC clone 
containing the DAT locus. 
The scheme represents the DATCreERT2 BAC construct, showing the position of the 
inducible Cre gene (iCreERT2), in the second exon in frame at the ATG of the DAT 
gene. 
 
 
 
3.7 Faithfull expression of the CreERT2 fusion protein in dopaminergic 
neurons  
Transgenic founder animals were identified by PCR (see material and 
methods). Two founders containing the transgene were identified and chosen 
for breeding with C57/Bl6 mice to establish transgenic mouse lines. Two 
different lines harboring the transgene (called Z1 and Z5) were used. The 
expression and nuclear translocation of the CreERT2 fusion protein upon 
tamoxifen treatment was investigated by immunohistochemistry (IHC) and 
immunoflorescence (IF) using midbrain vibratome sections containing SN and 
VTA. Transgenic animals were injected with either tamoxifen or vehicle 
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(sunflower oil) 12 hours before dispatch. In vehicle-treated animals the 
CreERT2 protein was located in the cytoplasm (Fig. 14a,b,e,f), whereas 
tamoxifen-treated animals displayed nuclear localization of the Cre 
recombinase in SN/ VTA (Fig. 14c,d,g,h).  
 
 
Figure 14:  Cre recombinase translocates into the nucleus only upon treatment 
with Tamoxifen.  
Brain sections of two transgenic mouse lines (Z1 and Z5) expressing the inducible 
Cre recombinase injected either with oil (a,b,e,f) or tamoxifen (c,d,g,h). Whereas in 
mice injected with oil the Cre recombinase resides in the cytoplasm, DATCreERT2 
transgenic mice injected with tamoxifen show nuclear translocation of the Cre 
recombinase in both transgenic lines Z1 (c,d) and Z5 (g,h). Scale bar, j, 100 µm; k, 
50 µm; inserts, 10µm. 
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3.8 Targeted tamoxifen-induced recombination in the adult SN/VTA 
To assess the ERT2-mediated control of the Cre recombinase activity in the 
absence of the ligand in dopaminergic neurons and to examine the efficiency 
of tamoxifen-induced Cre-mediated recombination, the different DATCreERT2 
mouse lines (Z1 and Z5) were crossed with ROSA26 Cre reporter mice 
(Soriano, 1999) to obtain ROSA26;DATCreERT2 mice. The Cre reporter line 
harbors a knock-in of the β-galactosidase (lacZ) gene followed by a stop 
cassette, which is flanked by two recognition sequences for the Cre 
recombinase (loxP). Upon tamoxifen treatment the Cre recombinase 
translocates into the nucleus and deletes the stop cassette thereby permitting 
β-galactosidase expression.  
ROSA26DATCreERT2 mice were injected twice per day with either tamoxifen 
(10mg/ml) or vehicle for five consecutive days (Erdmann, et al., 2007). Whole 
mount samples of the adult brain from the two DATCreERT2 lines were 
analyzed 10 days after the treatment for β-galactosidase activity.  
Determination of CreERT2 activity in the absence of the ligand revealed that 
ten weeks old vehicle-injected animals of the two transgenic lines showed 
very little β-galactosidase activity (Fig. 15a,d,g,i). Using whole mount staining 
no substantial differences were detected upon tamoxifen treatment between 
the two different DATCreERT2 transgenic lines in the SN/VTA (Fig. 15b,e,h,j).  
However, after tamoxifen treatment only the Z1 line shows β-galactosidase 
activity in dopaminergic neurons in the olfactory bulb and arcuate nucleus 
(Fig. 15c,f). 
 Further analyses were carried out using the DATCreERT2 line Z1 due to the 
better expression pattern of the Cre recombinase in dopaminergic neurons. In 
order to verify that recombination is restricted to dopaminergic neurons co-
labeling of LacZ activity (blue) and TH immunoreactivity (brown) (Fig. 16) was 
performed.  
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Figure 15:  Cre mediated recombination upon tamoxifen treatment 
β-galactosidase staining of brain slices from animals harboring a ROSA26 Cre 
reporter allele and the DATCreERT2 transgene. Staining reveals low Cre activity in 
absence of the ligand only treatment but strong staining within the substantia nigra 
(b,e), ventral tegmental area (h,j). In Z1 line (harboring higher number of 
DATCreERT2 transgene) Cre-activity could be additionally observed in the olfactory 
bulb and arcute nucleus (c,f). Scale bar, 400 µm. 
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Figure 16: Cre activity is restricted to dopaminergic neurons 
The activity of the Cre recombinase is restricted to dopaminergic neurons, as 
determined by LacZ staining (blue) in combination with TH immunohistochemistry 
(brown). The insert shows a higher magnification of double-stained neurons (arrows). 
Scale bar: 125 µm. 
 
 
 
 
 
3.9 Generation of the inducible TIF-IADATCreERT2 mice 
TIF-IAfl/fl mice (Yuan, et al., 2005) were crossed with DATCreERT2 mice to 
generate TIF-IAfl/fl; DATCreERT2 mice (TIF-IADATCreERT2), allowed to assess in 
detail the sequence of events happening after TIF-IA ablation, without 
developmental impairment.  
At the age of 2 months, mutant mice and control littermates were injected 
twice a day with 1 mg of tamoxifen for five consecutive days (Erdmann, et al., 
2007) and sacrificed at 7, 13 and 21 weeks after injection. 
Immunohistochemical detection of TH was used to analyze the loss of 
dopaminergic innervations of the striatum (Fig. 17a,c,e,g,i,k) and 
dopaminergic neurons in the ventral midbrain (Fig. 17b,d,f,h,j,l). After 7 
weeks, a significant decrease of TH immunoreactivity was observed in fibers 
of dopaminergic neurons in the striatum; whereas in the SN this reduction was 
much less pronounced (Fig. 17b). 
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 13 weeks after induction of Cre recombinase by tamoxifen, loss of TH 
immunoreactivity in the striatum (Fig. 17g) was associated with a major loss of 
dopaminergic neurons (Fig.  17h), culminating in an almost complete loss of 
dopaminergic neurons 21 weeks after induction (Fig. 17l).  
Vehicle injected control animals did not show any apparent loss of TH+ fibers 
in the striatum (Fig. 17a,c,e) or dopaminergic neurons in the midbrain (Fig. 
17a,c,e). TIF-IADATCreERT2 mutants also exhibited a progressive loss of TH+ 
fibers in the striatum (Fig. 17g) and dopaminergic neurons in the SN (Fig. 17h) 
and VTA (Fig. 17i), displaying differential vulnerability of these two 
subpopulations of dopaminergic neurons upon TIF-IA ablation in the adult.  
The quantification of neuronal loss was performed as previously described 
(Parlato, et al., 2006) and presented for fiber density in the striatum (Fig. 
17m), dopaminergic neurons located in the SN (Fig. 17n) and dopaminergic 
neurons residing in the VTA (Fig. 17o).  
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Figure 17: Progressive loss of dopaminergic neurons in TIF-IADATCreERT2 adult 
mice. 
(a-l) Loss of TH immunoreactivity in striata is visible in TIF-IADATCreERT2 mutants (c,d) 
7 weeks after tamoxifen injection compared to control (a,b), while TH+ neurons in 
SN/VTA are minimally affected. 13 weeks after injection, TH+ fibers in striata 
disappear almost completely (g) and severe loss of dopaminergic neurons in SN (h) 
is visible accompanied by partial loss of VTA TH+ neurons. Loss of dopaminergic 
fibers and neurons further advances 21 weeks after induction with tamoxifen (k,l). No 
changes are visible in the respective controls  at 7, 13 and 21 weeks (a,b), (e,f) and 
(i,j). (m) Quantification of the TH+ immunoreactivity in TIF-IADATCreERT2 mice in the 
striatum compared to respective control mice (n=5). (n,o) Percentage of remaining 
dopaminergic neurons in SN and VTA of mutants in comparison to control littermates 
(n=4; *, p<0.05; **, p<0.01; ***, p<0.001). Scale bars: k, 200 µm; l, 75µm. 
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As a next step locomotor activity of TIF-IADATCreERT2 mutants was monitored at 
different time points (8, 16 and 30 weeks) after tamoxifen-induced Cre 
expression. After 8 weeks, mutant and control mice did not exhibit significant 
differences in endurance time on accelerating wheel of the rotarod, consistent 
with the minor loss of dopaminergic neurons (∼20%) at this time (Fig. 18). At 
16 weeks, however, a progressive decrease in endurance time was observed, 
reflecting the decreased number of dopaminergic neurons after Cre-mediated 
TIF-IA ablation. In addition mutant mice display similar phenotypes as 
observed with the constitutive mutants (bradykinesia, rigidity, tremor).  Taken 
together, these results demonstrate that progressive loss of dopaminergic 
neurons in adult TIF-IADATCreERT2 mice leads to decreased locomotor activity 
and symptoms strikingly similar to those of observed in TIF-IADATCre mice and 
in Parkinson’s disease patients (Schober, 2004).  
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Figure 18: Loss of dopaminergic neurons in TIF-IADATCreERT2 adult mice results 
in progressive locomotor deficits. 
Locomotor deficits of TIF-IADATCre mice determined by the accelerating rotarod. No 
differences in motor performance are detectable 8 weeks after tamoxifen injection. 16 
weeks after injection the TIF-IADATCreERT2 mutants display a 35% reduction compared 
to the control group, reaching 75% reduction after 30 weeks. (n≥4; (*, p<0.05; ***, 
p<0.001).  
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3.10 Progressive loss of dopaminergic neurons is occasionally 
accompanied with Lewy body formation 
On the cellular level, PD is characterized by the occasional formation of 
cytoplasmatic proteinaceous inclusion bodies called Lewy bodies, consisting 
of parkin, synphilin, alpha-synuclein and ubiquitin.  Since TIF-IADATCreERT2 mice 
display progressive loss of neurons finally leading to motor impairment, it was 
interesting to see whether the mutation also induced the formation of Lewy 
bodies. Therefore mice were analyzed for specific markers of Lewy bodies 30 
weeks after tamoxifen injection. In comparison to control littermates 
expression of parkin (Fig. 19b) and synphilin (Fig. 19d) was increased, while 
ubiquitin (Fig. 19f) remained unchanged. Sporadically, immunohistochemical 
analysis showed neurons with α-synuclein accumulation in mutants (Fig. 19h). 
These inclusions could also be detected by hematoxylin and eosin (H&E) 
staining (Fig. 19j).  
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Figure 19: Increased expression of proteins associated with Lewy body 
formation.  
(a-j) Brain sections through the ventral midbrain were analyzed for parkin (a,b), 
synphilin (c,d), ubiquitin (e,f), α-synuclein (g,h) and hematoxylin/eosin (H&E) (i,j), as 
markers for Lewy body formation. While parkin and synphilin show higher expression 
in mutant mice, expression of ubiquitin and H&E are unchanged. Some inclusions 
could be observed which showed α-synuclein immunoreactivity. Scale bar: a-j, 25 µm 
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3.11 Linking nucleolar activity and mitochondrial integrity 
The results obtained with the inducible TIF-IADATCreERT2 mice encouraged us to 
assess in more detail the sequence of events that link nucleolar structure 
degeneration. TIF-IADATCreERT2 mice and control littermates were examined 1, 
2 and 4 weeks after tamoxifen injection, i.e. at times when no loss of DA 
neurons takes place. After 2 and 4 weeks there was a dramatic increase in 
the number of disrupted nucleoli in TH+ neurons of mutant mice (Fig. 20a). 
Again, nucleolar disruption was accompanied by overexpression of p53 (as 
previously shown) and reduction of COX activity in TIF-IADATCreERT2 mutants 
(Fig. 20b).  
 
 
 
 
 
 
Figure 20:  Disruption of the nucleolus is followed by increase in oxidative 
stress. (a) Quantification of nucleolar disruption in dopaminergic neurons in mice 1, 
2 and 4 weeks after tamoxifen injection of control and TIF-IADATCreERT2 mice, 
expressed as percent (%) of TH+ neurons showing translocation of NPM (n=4). (b) 2 
weeks after tamoxifen injection reduced COX activity in TIF-IADATCreERT2 mutants is 
measured as optical density in comparison to control mice (n=3; **, p<0.01). 
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Impairment of mitochondrial activity causes higher levels of ROS (Finkel, 
2005), which react with proteins, lipids and DNA. To analyze oxidative 
damage in TIF-IADATCreERT2 mutants, the total number of TH+ neurons in 
controls and mutants that are positive for nitrosylated proteins (NITT)(St-
Pierre, et al., 2006), neuroketals (NK) (Bernoud-Hubac, et al., 2001), and 
oxidized DNA (8-OHdG) (St-Pierre, et al., 2006) (Fig. 21a-f) was determined. 
Higher levels of nitrosylated proteins (Fig. 21a,b), neuroketals (Fig. 21c,d) and 
oxidized DNA (Fig. 21e,f) within dopaminergic neurons of TIF-IADATCreERT2 
mice were measured 4 weeks after tamoxifen injection (quantification shown 
in Fig. 21g). Remarkably, these alterations due to oxidative damage occur 
before structural changes in dopaminergic neurons or their projections to the 
striatum were observed (see Fig. 17a-o).  
In order to test the hypothesis that nucleolar activity and mitochondrial 
signaling are tightly linked, TIF-IADATCreERT2 and control mice were treated two 
weeks after Cre induction with MPTP or saline for 3 days, and dopaminergic 
neurons were analyzed one day after the last injection. A 15% reduction of 
TH+ neurons in control mice treated with MPTP was observed. As expected, 
TIF-IADATCreERT2 mutants treated with saline showed no significant difference in 
the number of TH+ neurons compared to control mice. In contrast, TIF-
IADATCreERT2 mice treated with MPTP displayed a considerably higher loss of 
dopaminergic neurons (∼42%) (Fig. 22) supporting the view that mitochondrial 
impairment affects the nucleolus. 
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Figure 21: Nucleolar disruption leads to increased oxidative stress 
(c-h) Brain sections through the ventral midbrain were analyzed for nitrosylated 
proteins (NITT) (c,d), neuroketals (e,f) and 8-hydroxydeoxyguanosine (8-OHdG) 
(g,h), as markers for ROS-induced cell damage (brown), in combination with TH 
staining (light blue) in order to identify dopaminergic neurons in mutants (d,f,h) 
compared to control littermates (c,e,g). Inserts show higher magnification of affected 
cells. (i) Quantification of dopaminergic neurons positive for oxidative stress markers 
in control and mutant mice 2 and 4 weeks after injection with tamoxifen. Differences 
are expressed as fold change in comparison to the mean of the controls at different 
stages. Higher levels of oxidative stress markers were observed in the mutants (n=4; 
*, p<0.05; **, p<0.01). Scale bar: c-h, 50μm. 
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Figure 22:  Linking nucleolar disruption with Parkinson’s disease. 
Effect of treatment with the neurotoxin MPTP on control and TIF-IADATCreERT2 mutant 
mice is analyzed 2 weeks after tamoxifen injection by counting the number of TH+ 
neurons. Control mice receiving saline show moderate loss of dopaminergic neurons 
upon MPTP treatment, while TIF-IADATCreERT2 mutants treated with the neurotoxin 
show a more severe reduction of TH+ neurons (n=5; *, p<0.05; **, p<0.01) 
 
 
 
 
3.12 Increased nucleolar disruption in dopaminergic neurons of PD 
patients 
The results obtained so far demonstrate that in dopaminergic neurons the 
nucleolus is involved in the oxidative stress response leading to mitochondrial 
impairment and the development of parkinsonism in TIF-IADATCreERT2 mice. 
These observations prompted to examine the occurrence of nucleolar 
impairment in cases of human PD. Therefore four different patients suffering of 
PD (P1-P4) were analyzed and compared to midbrains from ‘non-disease’ 
humans (C1-C4) obtained from the German Brain Bank. Humans from different 
gender and at different stages of the disease according to Braak (see Table 1) 
were analyzed. 
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Table 1: Formalin-fixed, paraffin-embedded sections of the midbrain from 4 
PD and 4 control cases were obtained from the German Brain Bank “Brain-
Net”. Demographic data:   
 
 Age at death [y] 
Post-mortem 
delay [h] 
Disease 
duration [y] Sex
Pathology stage 
according to  
Braak et al. 2003 
P1  76 7.5 10 M 6 
P2 63 24 16 M 4 
P3 72 11 10 F 5 
P4 71 20 >4 F 6 
C1 54 9.5 NA M 0 
C2 60 6.5 NA M 0 
C3 86 24 NA F 0 
C4 66 10 NA F 0 
 
 
 
The perturbation of nucleoli in TH+ neurons in clinically and pathologically 
confirmed cases of sporadic PD was quantified. In control sections the 
nucleolus is visible in a significantly higher percentage than in samples of PD 
(Fig. 23a,b). The quantification of our analysis reveals a strong increase in 
nucleolar disruption in PD cases (Fig. 23c). These findings show for the first 
time that the nucleolus is affected in PD, supporting the obtained results of the 
importance of the nucleolus in the neurodegenerative process occurring in PD.  
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Figure 23: Nucleolar integrity is decreased in dopaminergic neurons of humans 
suffering from PD 
(a,b) Example of human brain sections from controls (C1-C4) and PD patients (P1-
P4) analyzed for nucleolar disruption (NPM, brown) in dopaminergic neurons (TH, 
blue). Dopaminergic neurons of controls display clearly visible nucleoli (a) while in 
PD patients they are often disrupted (b) (scale bar: b, c - 15μm). (c) Quantification 
performed on 4 PD cases (of different pathology progression) compared with 
controls. Samples from SN/VTA region of PD patients reveal a dramatic decrease of 
TH+ neurons containing still visible nucleoli. Scale bar: c-h, 15μm.  
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4. Discussion   
 
The nucleolus is a specialized sub-nuclear compartment where rRNA is 
synthesized, processed, modified and associated with ribosomal proteins and 
5S rRNA before being exported to the cytoplasm. Apart from its traditional 
function as the ribosome-supplying organelle, the nucleolus has been shown 
to perform startling tasks in signal recognition and cell cycle regulation. One of 
the most intriguing novel roles of the nucleolus is the participation in sensing 
cellular stress signals and transmitting them to the p53 stabilization system 
(Boisvert, et al., 2007).  
In MPTP-induced parkinsonism and presumably also in Parkinson’s disease 
(PD), the main symptoms such as tremor and rigidity are attributed to the loss 
of dopaminergic neurons due to oxidative stress. In order to efficiently 
respond to hazardous conditions, cellular ROS sensors must exist to monitor 
oxidative stress and to respond towards it, for example, by regulating the 
expression of antioxidant genes or genes that promote cell death (Storz, 
2006).  
 
4.1 The nucleolus acts as a stress sensor in dopaminergic neurons 
The capacity of the nucleolus to react upon different stress stimuli has been 
shown (Mayer and Grummt, 2005). In order to analyze if the nucleolus is able 
to sense and respond towards oxidative stress in dopaminergic neurons, the 
well established neurotoxin MPTP was used to induce cellular stress only in 
dopaminergic neurons of mice. MPTP itself is not toxic but capable of crossing 
the blood-brain barrier. Once inside the brain, MPTP is metabolized into the 
toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the enzyme monoamine 
oxidase B (MAO-B) of glial cells.  The dopamine transporter shuttles MPP+ 
into dopaminergic cells, where it interferes with complex I of the electron 
transport chain, a component of mitochondrial metabolism. This blockage of 
the respiratory process in the mitochondria causes the buildup of free radicals 
that contributes to cell death (Przedborski and Vila, 2003, Schober, 2004).  
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The finding that MPTP treatment not only impairs mitochondrial function in 
dopaminergic neurons, but also affects the structure and transcriptional 
activity of RNA polymerase I (Pol I), suggests a link between nucleolar and 
mitochondrial function in MPTP-induced parkinsonism. Moreover it provides 
additional evidence for the notion that ribosomal biosynthesis acts as a ‘stress 
sensor’ in dopaminergic neurons. 
 
4.2 Generation of mice with artificial impairment of the nucleolus  
The decrease in Pol I dependant transcription after MPTP-induced oxidative 
stress revealed a functional interrelationship between the nucleolus and 
mitochondria. The key factor responsible for conveying extracellular signals 
towards the Pol I apparatus is TIF-IA, a Pol I-associated factor that regulates 
the transcriptional output in response to diverse signaling events (Grummt 
2003). It has been shown that in cells exposed to oxidative stress, TIF-IA is 
inactivated by JNK2-mediated phosphorylation and that rRNA synthesis is 
rapidly and efficiently shut-down (Mayer, et al., 2005, Yuan, et al., 2005).  
Conditions that inhibit Pol I transcription perturb the structure of the nucleolus 
(Mayer and Grummt, 2005). Ribosomal proteins, including L5, L11 and L23, 
and proteins found in the nucleolus as p19ARF or nucleophosmin (Kurki, et al., 
2004), (Lohrum, et al., 2003), are released from the nucleolus to the 
nucleoplasm, where they associate with MDM2. This association inhibits its 
activity and thereby stabilizes p53. It has been shown, that in mouse 
embryonic fibroblasts, depletion of TIF-IA leads to disruption of nucleoli, cell 
cycle arrest, upregulation of p53, and induction of apoptosis. RNAi-mediated 
knock-down of p53 can overcome proliferation arrest and apoptosis, 
reinforcing the central role of p53 in surveilling cellular health (Yuan et al., 
2005). 
To explore the consequence of perturbing this interrelationship nucleolar 
function was specifically ablated in dopaminergic neurons using Cre/loxP-
mediated ablation of TIF-IA an essential factor for the recruitment of Pol I. 
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Dopaminergic neurons react upon TIF-IA ablation with nucleolar disruption, 
p53 upregulation and later on mutant mice display reduced weight gain, 
exhibit abnormal behavioral symptoms, includes slowness of movements, gait 
and posture disturbances and resting tremor resembling closely PD 
symptomatology.  
Like in PD these locomotor abnormalities were associated with loss of 
dopaminergic neurons. While at birth mutant mice have a complete set of 
neurons, at later stages dopaminergic neurons were progressively lost. 
Intriguingly, dopaminergic neurons in the substantia nigra (SN) were more 
rapidly and strongly affected than those in the ventral tegmental area (VTA), 
mimicking the differential vulnerability of these two subpopulations of 
dopaminergic neurons in PD.  
The dramatic loss of dopaminergic neurons in PD patients impairs dopamine 
production, leading to alterations of the neural circuits that regulate movement 
(Lang and Lozano, 1998b, Lang and Lozano, 1998a). Striatal dopaminergic 
innervations (characterized by TH immunoreactivity) were affected long before 
dopaminergic neurons were lost, representing another characteristic of PD. In 
addition the striatal dopamine content of TIF-IADATCre was reduced by 95% at 
5 weeks of age. Reduced striatal dopamine transmission leads to impaired 
locomotor activity in TIF-IADATCre mutants, which we assessed using the 
accelerating rotarod assay. 
Together, these results demonstrate that ablation of TIF-IA leads to 
progressive loss of dopaminergic neurons in the SN and VTA, reduction of the 
striatal dopamine content and severely impaired locomotor performance, 
closely mimicking the symptoms in PD.  
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4.3 Treatment with L-DOPA restores normal locomotor performance 
in transgenic mice 
Parkinson's disease as a chronic disorder and the inevitable fact that at the 
present time there is no cure for it, medications or surgery provide the only 
form of treatment. The most widely used form of treatment is L-DOPA, the 
dopamine precursor (Birkmayer and Hornykiewicz, 1961). In order to verify if 
treatment with L-DOPA can rescue TIF-IADATCre mice from death, L-DOPA 
was injected either i.p. or continuously released by implanted pellets.  
While mutants without treatment with L-DOPA did not gain weight and died 
early, mutant mice treated with L-DOPA gained weight and were rescued from 
death. Moreover, increased growth of TIF-IADATCre mice was achieved 6 
weeks after continuous treatment by implanting subcutaneous pellets 
releasing a constant amount of L-DOPA. The data obtained demonstrate the 
responsiveness of TIF-IADATCre mice towards L-DOPA administration, 
recapitulating another important feature of PD.   
 
 
4.4 Impairment of nucleolar function affects mitochondrial activity 
and induces oxidative stress.  
Given the crucial role of mitochondrial dysfunction in PD and the interesting 
similarity of our model towards PD symptomatoloy, it became increasingly 
interesting to see whether nucleolar perturbation upon TIF-IA ablation results 
in mitochondrial dysfunction and whether oxidative stress is involved in 
damage of dopaminergic neurons in TIF-IADATCre mice (Dauer and 
Przedborski, 2003).  
To elucidate the molecular mechanism that triggers loss of dopaminergic 
neurons after TIF-IA depletion, we first assessed whether ablation of TIF-IA in 
dopaminergic neurons leads to alterations of nucleolar structure. TIF-IADATCre 
embryos at E18.5 were used and nucleolar integrity by immunofluorescence 
using antibodies against nucleophosmin and tyrosine hydroxylase monitored. 
In control cells, NPM is localized within the nucleoli, whereas in TIF-IADATCre 
mutants NPM is distributed throughout the nucleoplasm and p53 is 
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overexpressed. Mitochondrial impairment can be detected (among others) by 
reduced activity of the cytochrome c oxidase (COX) (Bender, et al., 2006, 
Ekstrand, et al., 2007). And indeed, at E18.5 TIF-IADATCre mutants showed 
strongly reduced levels of COX activity in the ventral mesencephalic area 
compared to control mice, indicating that loss of TIF-IA function affects 
mitochondrial activity.  
A constitutive Cre recombinase mouse line was used, which shows onset of 
expression before the development of the brain is completed (Parlato, et al., 
2006). Therefore phenotypical changes can arise from interferences of the 
mutation during brain development and/or from the deficiency of the 
respective protein in dopaminergic neurons. Although no difference of the total 
dopaminergic neuronal population at birth was visible, some alterations 
happen during embryogenesis, like nucleolar disruption and p53 upregulation 
due to ablation of TIF-IA. 
 
4.5 Generation of mice expressing an inducible Cre recombinase 
specifically in dopaminergic neurons  
In order to assess in more detail the sequence of events that link nucleolar 
with mitochondrial function in the adult mice and to avoid developmental 
deficits or compensatory effects, mutant mice expressing an inducible Cre 
recombinase have been generated, allowing the spatio-temporal control of the 
Cre-mediated recombination. The expression of the transgene, resembling the 
expression of the endogenous gene independently of the integration site, was 
ensured by the use of a BAC vector (bacterial artificial chromosome), 
containing large regions of genomic DNA with almost all regulatory elements 
of the gene (Casanova, et al., 2001, Parlato, et al., 2006). To target 
dopaminergic neurons exclusively, the regulatory elements of the mouse 
dopamine transporter gene were used to express the CreERT2 fusion protein 
in dopaminergic neurons of the adult mouse brain.  
Nuclear translocation of the CreERT2 is achieved by applying tamoxifen, which 
then allows Cre-mediated recombination (Indra, et al., 1999, Erdmann, et al., 
2007). Using the ROSA26 Cre reporter the effective temporal regulation of 
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CreERT2 activity by tamoxifen treatment was demonstrated. In the absence of 
the ligand very low recombination was detectable by whole mount staining 
only within the SN/VTA region. Treatment with tamoxifen resulted in strong 
recombination within dopaminergic neurons of the SN and the VTA. In 
addition, one of the analyzed lines displayed recombination in the olfactory 
bulb and the arcuate nucleus reflecting most precisely reported locations of 
dopaminergic neurons, which was then used to generate TIF-IA mutants.  
 
 
4.6 Inducible ablation of TIF-IA leads to nucleolar disruption  
The DATCreERT2 transgene was successfully employed in TIF-IADATCreERT2 
mice to achieve ablation of TIF-IA in dopaminergic neurons. Cre-induced 
inactivation of TIF-IA in adult mice (2 months old) leads to a similar  
neurodegenerative process as seen in PD (Conforti, et al., 2007). 13 weeks 
after induction of Cre recombinase by tamoxifen, loss of TH immunoreactivity 
in the striatum was associated with a major loss of dopaminergic neurons, 
culminating in an almost complete loss of dopaminergic neurons 21 weeks 
after induction. Interestingly, reduced TH immunoreactivity in the striatum 
precedes loss of the corresponding dopaminergic cells in the SN. This 
phenomenon has also been observed in parkinsonism (Lang and Lozano, 
1998a, Lang and Lozano, 1998b). Monitoring of TIF-IADATCreERT2 mutants 
revealed a progressive decline of locomotor activity, reflecting the decreased 
number of dopaminergic neurons after Cre-mediated TIF-IA ablation. 
Summarizing, conditional and inducible disruption of nucleolar integrity in 
dopaminergic neurons by specific ablation of the transcription initiation factor 
TIF-IA results in many of the hallmarks of parkinsonism, including progressive, 
but differential loss of dopaminergic neurons in the SN and VTA, progressive 
depletion of striatal dopamine projections, pronounced reduction of striatal 
dopamine content, responsiveness to L-DOPA treatment as well as marked 
deficiencies in animal motor performance (tremor, rigor, bradykinesia).  
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4.7 Increased expression of Lewy body components 
Another pathological characteristic of PD, besides loss of nigrostriatal 
dopaminergic neurons, is the presence of intraneuronal proteinaceous 
cytoplasmic inclusions, termed Lewy bodies. This abnormal deposition of 
protein in brain tissue is a feature of several age-related neurodegenerative 
diseases and not exclusive for PD. The composition and location of protein 
aggregates differ from disease to disease. It has been shown that the Lewy 
bodies in PD are a composition of parkin, synphillin, ubiquitin and alpha-
synuclein (Saudou, et al., 1998, Cummings, et al., 1999, Dauer and 
Przedborski, 2003). Analysis on TIF-IADATCreERT2 mice revealed a considerable 
difference in expression of parkin, synphilin and α-synuclein. This indicates a 
shift of protein expression in mutant mice during the neurodegenerative 
process. Since currently existing genetic animal models for this 
neurodegenerative disease have not been able to reproduce all the features 
of PD, the mouse mutants generated here provide a new tool to explore new 
treatments or implantation techniques for PD. 
 
4.8 Linking nucleolar activity and mitochondrial integrity 
Besides generating a valuable tool for PD research, another important and 
unexpected finding of this study was that the disintegration of the nucleolus by 
ablation of TIF-IA leads to mitochondrial impairment associated with increased 
oxidative stress before the survival of SN/VTA neurons is affected. The 
inducible mouse model (TIF-IADATCreERT2) enables to dissect different events 
happening after TIF-IA loss. So, one week after Cre-mediated ablation of TIF-IA 
a dramatic increase in the number of disrupted nucleoli in TH+ neurons of 
mutant mice was visible and associated with p53 upregulation.  
Interestingly, p53 has been shown to accumulate in the SN of sporadic cases of 
PD (Nair, et al., 2006) and in other neurodegenerative diseases, such as 
Huntington`s (striatum) or Alzheimer`s diseases (cortex) (Bae, et al., 2005, 
Alves da Costa, et al., 2006). Furthermore, the importance of p53-dependent 
cell death in dopaminergic neurons are strengthened by studies showing that 
p53-/- mice are resistant to MPTP toxicity (Trimmer, et al., 1996).  
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Two weeks after activation of the Cre recombinase, mitochondrial impairment 
was detectable by measuring COX activity in TIF-IADATCreERT2 mutants. The 
impairment of mitochondrial activity causes increasing ROS levels, which in turn 
react during the detoxification process with proteins, lipids or DNA. Higher levels 
of ROS scavenging products like nitrosylated proteins, neuroketals and oxidized 
DNA, within dopaminergic neurons of TIF-IADATCreERT2 mice were measured 4 
weeks after tamoxifen injection. Remarkably, the development of the 
abnormalities in mitochondrial function following blockade of rRNA signaling 
occur long before the loss of dopaminergic neurons begins (Fig. 24). 
 
 
 
 
Figure 24: Sequence of events observed in TIF-IADATCreERT2 mutants. Disruption of 
nucleolar integrity, clearly observed already 2 weeks after induction of the mutation by 
tamoxifen injection is followed by increased levels of ROS. This leads to 
neurodegeneration of dopaminergic neurons within SN and – after some delay – within 
VTA. When the amount of the cells in SN is reduced to approx. 20%, the animals start 
to show increased motor impairment (revealed by rotarod test). 
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In the context of control of the oxidative stress response, it is worth mentioning 
that the adaptor protein p66Shc, which directly stimulates ROS production 
(Orsini, et al., 2004, Giorgio, et al., 2005), has been shown to act as a 
downstream target of p53 and to be crucial for p53-dependent mitochondrial 
ROS production. Interestingly, p66Shc null mice are resistant to paraquat, a 
pesticide that induces selective dopaminergic degeneration (Dauer and 
Przedborski, 2003). It remains to be elucidated how nucleolar disruption and 
p53 upregulation directly affects mitochondrial activity.  
In order to test the hypothesis that nucleolar activity and mitochondrial signaling 
are tightly linked, TIF-IADATCreERT2 and control mice were treated two weeks after 
Cre induction with MPTP or saline. TIF-IADATCreERT2 mice treated with MPTP 
displayed a considerably higher loss of dopaminergic neurons than control mice 
treated with MPTP, supporting the view that mitochondrial impairment affects 
the nucleolus. It seems that within dopaminergic neurons higher ROS levels are 
sensed by the nucleolus, as indicated by the pronounced decrease of RNA 
polymerase I activity one day after MPTP treatment. In turn inhibition of 
transcription disturbed nucleolar structure, causing release of nucleolar 
components, triggering p53 stabilization, leading to the impairment of 
mitochondrial activity and finally promoting cell death. Although other 
mechanisms linking nucleolar and mitochondrial function cannot be excluded, 
the data suggest the existence of a self-reinforcing loop that can be activated at 
several levels once a threshold of injurious stimuli is passed (Fig. 25).  
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Figure 25: Schematic representation of a model linking mitochondria and 
nucleolar activity.  
Toxic insults directed to mitochondria, such as the treatment with MPTP, increase the 
production of ROS. The nucleolus responds by downregulating rRNA synthesis. By 
TIF-IA ablation, changes in nucleolar integrity and activity alter the turnover of p53, 
leading to impairment of mitochondria and increased oxidative stress. Increased p53 
levels may activate the apoptotic machinery at the mitochondria, leading to even higher 
accumulation of ROS and causing a sustained stress eventually lethal for the cell. 
 
 
 
 
This model is further supported by the observation that an intact nucleolus is 
crucial for the resistance to oxidative insult produced by MPTP treatment. The 
mitochondrial damage following TIF-IA loss leads to increased ROS production, 
which will further worsen the mitochondrial damage. Once this vicious cycle is 
adopted, increasing levels of free radicals progressively consume the 
antioxidant capacity, ROS production overcomes its removal and further 
mitochondrial deficiencies will ensue.   
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4.9 Increased nucleolar disruption in dopaminergic neurons of PD 
patients 
The phenotype of the mutants lacking TIF-IA suggests a novel and unpredicted 
role of the nucleolus and its function in the pathophysiological processes 
involved in parkinsonism. This notion is substantiated by the observation that 
PD patients display increased perturbation of nucleoli in dopaminergic neurons 
compared to control cases.  
Based on the findings reported here, a correlation between impaired nucleolar-
dependent activities and increased sensitivity to oxidative stress as observed in 
some genetic forms of PD is likely to exist. It has been reported that the protein 
DJ-1, associated with familial cases of PD, inhibits the tumor suppressor PTEN 
(Kim, et al., 2005b). PTEN in turn is known to inhibit the activity of RNA 
polymerase I (Zhang, et al., 2005). Therefore, a very attractive possibility is that 
loss of DJ-1 in PD patient results in increased PTEN activity and inhibition of 
rRNA synthesis. Disruption of nucleolar integrity in PD patients would make 
neurons more vulnerable to oxidative stress. In this context it is interesting that 
DJ-1-deficient mice are also hypersensitive to MPTP (Kim, et al., 2005a) and 
that inactivation of DJ-1 in Drosophila melanogaster increases sensitivity to 
oxidative stress (Yang, et al., 2005).  
Given the crucial role of the nucleolus in the oxidative stress response, it is 
reasonable to propose that TIF-IA ablation and subsequent nucleolar 
impairment in the dopaminergic neurons of mutant mice mimic, at least partially, 
the chain of events leading to cell death in PD. Therefore, it is important to 
unravel in which way structural and functional perturbations of the nucleolus are 
involved in the development of the pathophysiology of PD. Thus, these studies 
are of clinical importance to develop procedures aimed to alleviate the 
consequences of this neurodegenerative disease.   
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5. Materials and Methods 
 
5.1 Materials 
5.1.1 Chemicals and enzymes 
Chemicals and enzymes were in general purchased from the following 
companies:  
 
Chemicals: 
BioRad, Munich 
Difco, Detroit 
Fluka, Neu-Ulm 
VWR International, Darmstadt 
Roth, Karlsruhe 
Serva, Heidelberg 
Sigma-Aldrich, Munich 
Applichem, Darmstadt 
 
 
Enzymes: 
Roche, Mannheim 
New England Biolabs, Schwalbach 
Invitrogen, Karlsruhe 
Stratagene, Heidelberg 
Promega, Heidelberg 
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5.1.2 Standard solutions 
 
 
10x PBS (phosphate buffered saline) 
1,37 M  NaCl 
100mM Na2HPO4 
27mM  KCL 
20mM  KH2PO4 
pH 7.2 
optional ? 1ml DEPC/1l, stirred and autoclaved 
 
 
 
TE 
10mM  Tris/HCl, pH 8 
1mM  EDTA, pH 8 
 
 
 
50x TAE (Tris acetate EDTA buffer) 
2M   Tris base 
50mM  EDTA 
250mM  NaAc 
pH 7.8 (glacial acidic acid) 
 
 
 
20x SSC (standard sodium citrate buffer) 
3M  NaCl  
0,3M  sodium citrate 
pH 7 
 
 
10x TBE 
2M  Tris 
250mM NaAc 
50mM  EDTA 
pH 7.8 (glacial acetic acid) 
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5.1.3 Plasmids 
PIndu: The plasmid generated and provided by Dr. Erich Greiner (Evotec, 
Germany) was used to clone the construct for the knock-in of a CreERT2 
cassette at the ATG of the dopamine transporter gene present on a large 
genomic fragment (BAC vector) by homologous recombination in bacteria. 
The plasmid contains a cassette encoding a fusion protein consisting of the 
codon-improved Cre recombinase (Shimshek, et al 2002) and a mutated 
ligand-binding domain of the human estrogen receptor (Feil et al, 1997). In 
addition the plasmid harbors an ampicillin resistance cassette flanked by two 
FRT sequences, which can therefore be removed by the Flp recombinase. 
 
5.2 Plasmid constructs and probes 
DNA fragments were generally cloned into pBluescript II KS (+/-) vector 
(Stratagene) 
 
 
5.3 Standard techniques in molecular biology  
5.3.1 Cloning into plasmid vectors and sequencing 
Cloning of DNA fragments into plasmid vectors was performed following the 
established standard protocols in Sambrok et al. (1989) and is therefore not 
described here. Methods to obtain DNA fragments or vectors and to clone 
different plasmid constructs included digestion with restriction enzymes, 
dephosphorylation of DNA ends with Shrimp alkaline phosphatase (Roche), 
phosphorylation of DNA ends with polynucleotidekinase, as well as, ligation of 
DNA fragments using T4-DNA-polymerase. Isolation of DNA fragments out of 
agarose gels was performed using the Qiaquick Gel-Extraction Kit (Qiagen) 
according to manufacturer’s instruction. Competent bacteria of the strain 
E.Coli NM554 were generally transformed by heat-shock at 42°C. 
Recombinant plasmid DNA was then isolated from the bacteria as described 
before. 
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5.3.2 Isolation of DNA 
 
5.3.2.1 Miniprep of plasmid from bacteria DNA from bacteria  
 
This method was adapted from Holmes and Quigley, 1981 and is suitable for 
preparation of small amounts of DNA to screen a large number of bacterial 
clones. 1ml of an O/N bacterial culture was centrifuged for 30s at 13.000rpm 
and resuspended in 400µl STET buffer. After incubation of the preparation 
with 32µl lysozyme solution (10µl/ml), the Miniprep was heated up to 95°C for 
2min, cooled down at 4°C for 30min and subsequently centrifuged for 15min, 
at 4°C with 14.000rpm. The pellet was removed using a blue tip and 800µl 
EtOHabs were added to the remaining supernatant followed by 10min 
incubation at RT. The preparation was centrifuged afterwards for 10min at 
4°C with 14.000rpm, the supernatant was removed and the pellet was washed 
once with 70% EtOH, subsequently air dried and dissolved in 100µl TE.  
 
STET buffer 
50mM  Tris/Hcl, pH8 
50mM  EDTA 
5%  Trition-X-100 
8%  sucrose 
 
 
5.3.2.2 Miniprep of BAC DNA 
 
The size of a BAC (about 150kb circular supercoiled DNA) and its low 
abundance in a bacterial culture (1-2 copies/bacterium) requires a different 
preparation method than the one used for plasmid DNA. The bacterial 
colonies were inoculated in 2ml LB medium containing chloramphenicol 
(25µl/ml). After centrifugation (4000rpm, 10min, 4°C), the culture was 
resuspended in P1, the bacterial membrane was destroyed by alkaline lysis 
with P2 and the lysate was neutralized using P3 (P1, P2, P3 buffers, Qiagen). 
The preparation was then centrifuged (14.000rpm, 10min, 4°C), the 
supernatant was transferred into a new tube and 600µl isopropanol were 
added. After centrifugation (14.000rpm, 10min, 4°C) the pellet was washed in 
70% EtOH, dried and resuspended in 40µl TE. The concentration and quality 
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was verified by gel electrophoresis after appropriate restriction-digestion of the 
BAC.  
 
5.2.2.3         Midiprep of BAC DNA 
 
Midiprep of BAC DNA was performed using Q20-columns and regents from 
Qiagen. The BAC-positive bacterial colonies were inoculated in 50ml LB-
medium containing chloramphenicol (25µl/ml). The preparation of the 
neutralized lysate was performed as described for Miniprep with 5ml of each 
of the buffers. The lysate was centrifuged at 4000rpm at 4°C for 20min and 
filtered through cheesecloth. The DNA was precipitated by addition of 10ml 
isopropanol and subsequent centrifugation (4000rpm, 4°C, 20min). The pellet 
was resuspended in 1ml QBT buffer (Qiagen) and applied to a Q20-column 
(equilibrated with 1ml QBT) for 5min. After 3 washing steps with 2ml QC 
buffer (Qiagen), the DNA was eluted twice with 800µl of preheated (70°C) QF 
buffer (Qiagen) and precipitated with 560µl isopropanol followed by 15min 
centrifugation with 14.000 at 4°C. The pellet was washed with 70% EtOH, 
dried and resuspended in 25µl TE. The concentration and quality was verified 
by gel electrophoresis after appropriate restriction digestion of the BAC: For 
preparation of the BAC DNA for microinjection the pellet was resuspended in 
10µl TE, incubated for 10min at RT and exonuclease activity was then 
inactivated by 15min incubation at 65°C.  
 
 
5.4 Generation of transgenic mice 
5.4.1 Modification of a BAC by homologous recombination in bacteria 
Recombinant DNA molecules can be generated by homologous 
recombination in bacteria (ET-cloning) using the method of Copeland and 
Court (Lee, et al., 2001). This method allows the integration of a linear DNA 
sequence into a homologous region of an acceptor vector.  
The BAC used to generate for the DATCre transgene (Parlato, et al., 2006) 
was modified by homologous recombination in EL250 cells to insert a cassette 
encoding a fusion protein (CreERT2) consisting of a codon-improved Cre 
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recombinase (Cre) (Shimshek, et al., 2002) and a mutated ligand-binding 
domain of the human estrogen receptor (ERT2) (Feil, et al., 1997) as well as 
an ampicillin resistance cassette flanked by two FRT sites. 
 
5.4.2 Preparation of competent bacteria for transformation with the 
BAC 
Single colonies of EL250 bacteria (Copeland/Court) were inoculated in 5ml 
LB-medium at 32°C. 2ml of the O/N culture were transferred into 50ml LB-
medium and incubated at 32°C for 3-4hrs. When cells reached the log phase 
(OD=0.4-0.5), they were cooled on ice and centrifuged for 10min at 4°C, 
4000rpm. The cell pellet was resuspended in 50ml of ice-cold 10% glycerol 
and centrifugation as well as resuspension in 10% glycerol was repeated 
twice. After the last washing, the supernatant was poured off. The pellet was 
resuspended in the remaining 10% glycerol resulting in a final volume of 0.6-
0.7ml. 50µl aliquots of the cells were transferred into pre-cooled Eppendorf 
tubes and frozen in liquid nitrogen.  
 
5.4.3 Re-transformation of the BAC 
Miniprep of the BAC was prepared as described above. The competent EL250 
cells were thawed on ice and the electroporation cuvettes were pre-cooled on 
ice. A series of 1µl, 2µl and 5µl of the BAC miniprep were added to 50µl 
competent cells respectively, followed by electroporation at 2.3kV (BioRad 
Gene Pulser, 25µF with Pulse controller set to 200Ω). 1ml LB-medium was 
added afterwards, the cells were transferred into eppendorf tubes and 
incubated for 1h at 32°C. Finally 100µl of the cells were plated directly on LB-
plates containing chloramphenicol (25µg/ml), whereas the remaining cells 
were centrifuged, resuspended in 100µl LB-medium and plated on a second 
chloramphenicol plate. 
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5.4.4 Preparation of competent bacteria for homologous recombination 
Single colonies were picked from EL250 bacteria containing the desired BAC 
clone and inoculated in 5ml LB-medium/chloramphenicol (25µg/ml) at 32°C 
O/N. Next day 2ml of the O/N culture were transferred into 50ml LB-medium 
and incubated at 32°C for 3-4hrs. When cells reached the log phase (OD=0.4-
0.5), the RED-recombination system was induced by 15min shaking in a 42°C 
water bath. After incubation, the cells were rapidly cooled down and incubated 
on ice for 10-40min. Subsequent washing steps with 10% glycerol, 
resuspension and freezing in 50µl aliquots followed, as described previously. 
 
5.4.5 ET recombination and removal of the ampicillin resistance 
cassette 
0.1pmol of the linearized and purified CreERT2 construct were electroporated 
into the RED-induced bacteria at 2.3kV (BioRad Gene Pulser, 25µF with 
Pulse controller set to 200Ω). The cells were incubated in additional 1ml LB-
medium for 1h as described before (5.3.1.3.) and plated on LB-plates 
containing chloramphenicol (25µg/ml) and ampicillin (50µg/ml) followed by 
incubation at 32°C (at least for 16hrs). Colonies were picked and BAC 
minipreps were performed as described, followed by diagnostic digestion with 
frequent cutting enzymes to verify successful ET-recombination. 
The CreERT2 construct contains an ampicillin resistance cassette to select for 
the BAC that underwent homologous recombination with the construct. After 
homologous recombination in bacteria the resistance cassette was removed 
from the modified BAC. Since the cassette is flanked by two FRT sequences, 
it can be excised by Flp-recombinase, which can be induced in EL250 
bacteria by L-arabinose (Sigma). Of the recombined clone 5ml O/N culture 
(containing 25µg/ml chloramphenicol) were incubated at 32°C and the next 
day a 1:50 dilution of the culture was prepared and incubated at 32°C until 
cells reached OD of 0.5. Then cells were treated for 1h with 0.1% L-arabinose 
at 32°C, diluted 1:10, incubated an additional hour and were plated onto 
chloramphenicol (25µl/ml) LB-plates followed by incubation at 32°C. After O/N 
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incubation, colonies were picked and transferred into 5ml LB medium 
(containing 25µg/ml chloramphenicol). After O/N incubation, a small aliquot of 
the culture was incubated for few hours in LB-medium containing 
chloramphenicol (25µl/ml) and ampicillin (50µg/ml) to verify the loss of the 
ampicillin resistance cassette by negative selection. From a culture that was 
not growing in ampicillin LB-medium, a BAC Miniprep was performed with 
subsequent diagnostic digestion by analytical pulse-field gel electrophoresis. 
 
5.4.6 Preparative and analytical pulse-field gel electrophoresis 
The modified genomic fragment containing the CreERT2 knock-in at the ATG 
of the DAT gene was released from the BAC backbone by NotI digestion. For 
this purpose, 100µg BAC DNA, isolated according to the BAC Midiprep 
protocol, were digested O/N with NotI and heat inactivated the next day for 
10min at 65°C. The linearized recombined genomic insert was purified by 
preparative pulse-field gel electrophoresis (PFGE) (Schedl, et al., 1993). 50µg 
of the digested BAC DNA were resolved on a 1% Sea-plug low-melting-point 
agarose (Sigma) gel in 0.5xTAE running buffer using the following 
parameters: initial tswitch = 0.2s, final tswitch = 12s, included angle a = 106°, ⏐E⏐ 
= 6V/cm, I ≅ 140mA, total time t= 14h. For determination of the gel area to be 
cut out, only the gel parts containing the marker were stained with 
ethidiumbromide. The gel piece containing the genomic insert of the BAC was 
isolated according to the marker-bands and the agarose was digested with µ-
agarose (Sigma) at 40°C for 20min. Non-digested agarose was removed and 
the DNA was purified using centrifugation cartridges. For microinjection of the 
modified genomic fragment into mouse oocytes, the DNA was further purified 
by dialysis with microinjection buffer for 2-3hrs. The concentration of the DNA 
preparation was estimated on a 0.8% agarose gel using various amounts of a 
linearized plasmid of the same size. The integrity of the DNA sample was 
verified by analytical PFGE, which was performed like the preparative PFGE 
with the exception that the entire gel, prepared with standard agarose, was 
stained with ethidiumbromide in order to detect the DNA fragments.  
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Agarase buffer 
10mM  Tris/HCl, pH 6.5 
1mM  EDTA 
100mM NaCl 
30µM  spermine (Sigma) 
70µM  spermidine (Sigma) 
 
Microinjection buffer 
10mM  Tris/HCl, pH 7.5 
0.1M  EDTA 
100mM NaCl 
 
 
 
5.4.7 DNA microinjection in mouse oocytes 
The microinjection of DNA into mouse oocytes was performed according to 
the protocol of Hogan (Hogan et al., 1994). Superovulated fertilized FVB/N 
females were used as source of oocytes. To induce superovulation, females 
were first injected intraperitoneally with PMS-gonadotropin (Sigma) and 48 
hours later with chorion-gonadotropin (Sigma). After administration of chorion-
gonadotropin, the females were mated with FVB/N males and were analyzed 
for the presence of a vaginal plaque the following morning. Positive females 
were sacrificed the morning after the mating by cervical dislocation, the 
oviducts were removed and transferred into 37°C-warm M2-medium. Oocytes 
were isolated and cumulus cells surrounding the oocytes were removed by 
hyaluronidase treatment (100mg/ml in M2-medium; Sigma). Oocytes were 
then rinsed in M2-medium, transferred into M16-medium and incubated at 
37°C. For microinjection, 30 oocytes were transferred in an injection syringe 
containing M2-medium and placed under a microscope with two 
micromanipulator setups connected to a hydraulic control system (Eppendorf 
femtoJet). Oocytes were fixed with a blunt pipette and the tip of the injection 
needle was filled with the prepared DNA. The DNA was injected at a 
concentration of 1µg/µl or 2µg/µl in a volume of 1-2pl into the larger male 
pronucleus and oocytes were subsequently incubated for 2hrs in M16-medium 
at 37°C and controlled for their vitality.  
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To transfer the oocytes into foster mothers, pseudo pregnant FVB/N females 
(mated with vasectomized males one day before) were intraperitoneally 
injected with Ketavet and Rompun (0.01ml of a 1:10 in PBS diluted solution 
per g bodyweight) to anesthetize the animals. To transfer the oocytes, the 
operation site was desinfected with EtOH, the abdominal cavity was opened 
and the oviduct was pulled out. Using a binocular the oocytes were injected 
into the oviduct, it was returned to the abdominal cavity and the wound was 
closed with clamps. The females delivered 18 days after the surgery and 5-
15% of the offspring were expected to be transgenic. 
 
 
M2-medium 
20ml  10xA 
3.2ml  10xB 
2ml  33mM sodium pyruvate (Serva) 
2ml  171.4mM CaCl2 (H2O)2 
16.8ml 250mM HEPES (sodium salt, Sigma) 
156ml  H2O 
800mg BSA (Serva) 
pH 7.4 (NaOH) 
 
 
M16-medium 
20ml  10xA 
20ml  10xB 
2ml  33mM sodium pyruvate (Serva) 
2ml  171.4mM CaCl2 (H2O)2 
156ml  H2O 
800mg BSA (Serva) 
pH 7.4  NaOH) 
 
10xA       10xB 
47mM  NaCl     250mM NaHCO3 
47.75mM KCl     max. 5mg phenolred 
11.9mM KH2PO4    
232.8mM sodium lactate (Sigma)  
55.6mM D-glucose    
0.6g/l  penicillin (Seromed)   
0.5g/l  streptomycin (Seromed)  
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5.5 Genotyping 
All primers used for PCR were ordered at MWG Biotech AG, Munich.  
 
5.5.1 Isolation of genomic mouse DNA by NID lysis buffer 
The DNA used for the PCR was obtained as followed: from adult mice we 
used a piece of the tail (about half centimeter), from embryos the whole tail 
and from organs a small piece (approximately 100 mm3). The pieces were 
additionally washed in PBS in order to limit possible contaminations between 
tissues of different samples. Afterwards they were digested over-night at 56°C 
in 200μl of NID buffer, which is a non-ionic detergent buffer, added with 2μl of 
proteinase K (10mg/ml). The proteinase K was inactivated the following day at 
95°C for 15 min. After collecting the possible condense by centrifugation, the 
NID-lysates were used for genotyping by PCR.  
 
NID buffer 
 
50 mM KCl 
10 mM Tris pH8.3 
2 mM   MgCl2 
0.1 mg/ml  gelatine 
0.45%  NP40 
0.45%  Tween 20 
1 mg/ml  proteinase K 
 
5.5.2 Polymerase Chain Reaction (PCR) 
The PCR was done in a Thermocycler Gene Amp PCR system 9700 (Applied 
Biosystems) with the following primers and protocols: 
 
 
DATCre transgene 
5`-primer/Cre212:  5`-CTGCCAGGGACATGGCCAGG-3’ 
3`-primer/Cre213:  5`-GCACAGTCGAGGCTGATCAGC-3’ 
Expected PCR products:  wild-type:  no band  
    mutant: 500bp 
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NIDprep-DNA 2 µl      
10x buffer with MgCl2 2,5 µl  PCR  condition 
dNTPs (5mM) 2 µl  95°C 5 min   
Primer 212 (10pmol/µl) 1 µl  95°C 1 min   
Primer 213 (10pmol/µl) 1 µl  60°C 1 min 35 x
Taq-polymerase (1U/µl) 1 µl  72°C 2 min   
sterile water 16,5 µl  
  
72°C 10 min   
Final volume 25 µl      
 
 
DATCreERT2 transgene: 
Cre2 Fw:    5`-GGC TGG TGT GTC GTC CAT CCC TGA A-3’ 
Cre2 Rev:  5`-GGT CAA ATC CAC AAA GCC TGG CA–3’ 
Expected PCR products:  wild-type:  no band 
mutant: 405bp 
 
 
NIDprep-DNA 2 µl      
10x buffer with MgCl2 2,5 µl  PCR  condition 
dNTPs (5mM) 2 µl  95°C 3 min   
Cre2 Fw (10pmol/µl) 1 µl  95°C 45 sec   
Cre2 Rev (10pmol/µl) 1 µl  60°C 1 min 35 x
Taq-polymerase (1U/µl) 1 µl  72°C 2 min   
sterile water 16,5 µl  
  
72°C 10 min   
Final volume 25 µl      
 
 
 
ROSA-LacZ transgene: 
ROSA-1:    5`-TCT GCT GCC TCC TGG CTT CTG A-3’ 
ROSA-2:  5`-CCA GAT GAC TAC CTA TCC TCC CA –3’ 
ROSA-3: 5`-AAG CGC ATG CTC CAG ACT GCC T –3’ 
Expected PCR products:  wild-type:  270bp 
mutant: 420bp 
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NIDprep-DNA 2 µl      
10x buffer with MgCl2 2,5 µl  PCR  condition 
dNTPs (5mM) 2 µl  95°C 3 min   
ROSA-1 (10pmol/µl) 1 µl  95°C 45 sec   
ROSA-2 (10pmol/µl) 1 µl  63°C 1 min 35 x
ROSA-3 (10pmol/ml) 1 µl  72°C 2 min   
Taq-polymerase (1U/µl) 1 µl  
  
72°C 10 min   
sterile water 16,5 µl      
Final volume 25 µl      
 
 
 
TIF-IA –locus: 
TIF-IA FWD:  5`-CCG GTG GTC CTG CTT ACA CTA GAGATGTGG-3’ 
TIF-IA REV:  5`-AATATAATT TGC AGC AGCCTGCCTGATGATGG–3’ 
Expected PCR products:  wild-type:  680bp 
mutant: 760bp 
 
NIDprep-DNA 2 µl      
10x buffer with MgCl2 2,5 µl  PCR  condition 
dNTPs (5mM) 2 µl  95°C 3 min   
TIF-IA FWD (10pmol/µl) 1 µl  95°C 45 sec   
TIF-IA REV (10pmol/µl) 1 µl  61°C 45 sec 35 x
Taq-polymerase (1U/µl) 1 µl  72°C 1,5 min   
sterile water 16,5 µl  
  
72°C 10 min   
Final volume 25 µl      
 
5.5.3 Agarose gel electrophoresis 
The PCR products were analyzed by electrophoresis on agarose gel. The 
agarose was dissolved in 0.5x TBE and 5μl of ethidiumbromide (10mg/ml) 
were added to 100 ml of dissolved gel. For the PCR products a 1.5% agarose 
gel was used. As a marker 2.5 μl of Smartladder (EUROGENTEC) were also 
loaded on the gel to define the size of DNA bands. All samples contained 
1xloading solution when loaded to the gel.  
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5.6 RNA analysis – in situ hybridization 
5.6.1 Synthesis of digoxigenin (DIG) -labeled RNA-probes 
The generation of single-stranded digoxigenin(DIG)-labeled RNA-probes was 
performed by in vitro transcription of a DNA-template. As template served a 
linearized plasmid; containing the appropriate sequence and promoters for 
RNA-polymerases flanking the probe sequence. Depending on the orientation 
of the probe sequence and the plasmid either T7 or SP6 was used to 
generate the anti-sense probe. The sense probe was synthesized using the 
other RNA-polymerase.  
 
5.6.2 Synthesis of riboprobes by using PCR products as template 
The DNA obtained was used for a PCR with M13 primers, contained in the 
vector, in order to amplify the cloned DAT fragment within.  
 
M13 PCR       
10x buffer with MgCl2 2 µl     
dNTP (10 mM) 0,5 µl     
Primer M13 forward (10 pM) 2 µl  PCR 
Primer M13 reverse (10 pM) 2 µl  95°C 4 min   
Taq-polymerase (1 U/µl) 0,5 µl  95°C 30 sec 
Sterile water 12 µl  63°C 30 min 
DNA   72°C 30 min 
35 x 
(Plasmid preparation 100 ng/µl)
1 µl 
 72°C 7 min   
 
 
The amplified DNA was used (without purification) for the in vitro transcription.  
To label the RNA, a DIG RNA Labeling Mix, 10x conc. (from Roche) was 
used. Digoxigenin-UTP is incorporated by SP6 or T7 RNA polymerase at 
approximately every 20-25th nucleotide of the transcript under the conditions 
described below: 
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In vitro translation  
DNA (not purified PCR product) 1 μl 
10x transcription buffer Roche 2 μl 
DTT 100 mM 2 μl 
10x RNA labelling mix (Roche) 2 μl 
RNase inhibitor (Roche) 1 μl 
T7, Sp6 RNA polymerase 
(Roche) (20 U/μl) 
1 μl 
DEPC water 11 μl 
Final volume 20 μl 
  
This reaction was incubated for 2 hours at 37°C. To digest the DNA template 
2 μl of DNase I (10 U/μl) were added to each tube and left at 37°C for 15 min. 
The synthesized RNA was added with 30 μl of DEPC- H2O and kept in ice. To 
purify the riboprobes from the not incorporated components, G50 spin 
columns were used. The lid and the tip are removed and the columns were 
centrifuged. The transcription mixture is loaded to the middle of the column 
and centrifuged 2 min at 3500 rpm. The flow-through is recovered, 4 μl of this 
are used to check the quality of the probe on a denaturating RNA gel and 
other 2 μl are used to check the yield of the RNA synthesis. 
 
5.6.3 Denaturating RNA gel 
For 50 ml of the gel 0,6g of agarose were diluted in 5 ml of MOPS and 37,5ml 
of DEPC-treated H2O. The agarose was dissolved by microwave for 3 min at 
600 watt, cooled down to 40°-50°C and 7,5ml of formaldehyde were added. 
The gel was poured in RNase free apparatus for electrophoresis.  For 4 μl of 
sample, 12 μl of RNA loading buffer were used to load the sample in the gel. 
As a marker an already labeled control RNA (from the RNA labeling kit; 
Roche) was used in different concentrations. 
The electrophoresis buffer was 1x MOPS, which was diluted from 10x MOPS 
with DEPC-treated H2O. 
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5.6.4 RNA dot blot 
To define the exact amount of the RNA probes, serial dilutions of the purified 
riboprobe were made. This was also done with the already labeled control 
RNA, which has the concentration of 100 ng/μl.  1μl of the labeled probe and 
diluted control RNA is spotted on a nylon membrane. The nucleic acids were 
fixed by cross-linking with UV-light (Stratalinker UV 1800, Stratagene) by 
using the auto crosslinking mode. The next step was to incubate the 
membrane with blocking solution (gentle shaken) for 30 min at RT. Anti-DIG 
alkaline phosphatase was diluted 1:5000 in blocking solution. The entire 
membrane had to be covered with the antibody dilution. After the incubation, 
the membrane was washed two times for 15 min with washing buffer. The 
washing buffer was removed and the color substrate of alkaline phosphatase 
BM purple (Roche) is added. The reaction was protected from light. After one 
hour the spots had a sufficient intensity the reaction was stopped by washing 
the membrane for five min in sterile water. To examine the amount of the 
labeled probes, the intensity of the diluted riboprobe was compared with the 
control.  
 
5.6.5 In situ hybridization on paraffin sections 
All solutions and equipment, used for the pre-hybridization steps should be 
RNase free. Stock solutions are therefore treated with DEPC and diluted in 
DEPC water. The paraffin slides were dewaxed in xylene 2 times for 10 min. 
The dehydration of the sections is done, by using a decreasing EtOH series: 
two times 5 min in 100% Ethanol and then 95%, 70%, 50% and 30% ethanol 
for 1 min each. Finally, they were washed two times for 5 min in PBS. To post-
fix the sections 4% PFA was used for 20 min. Then the slides were washed 
two times 5 min in PBS. To make the RNA more accessible to the riboprobes, 
the slides were incubated with proteinase K solution for 6 min 30 seconds. 
Proteinase K solution was washed with PBS for 5min. The sections were fixed 
again in 4% PFA solution for 30 min. Two washing steps with PBS for 5 min 
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followed and another two times for 2 min in 2x SSC. The sections were left in 
Tris/Glycine buffer for 30 min.  
 
Hybridization mix: 
 
Hybridization mix Final conc. 100 μl/slide 
100% formamide 40% 40 μl 
20x SSC pH 4,5 5x 25 μl 
50x Denhardt’s 1x 2 μl 
10 mg/ml salmon sperm DNA 100 μg/ml 1 μl 
10  mg/ml tRNA 100 μg/ml 1 μl 
H2O DEPC treated  30,9-30,8 μl 
Probe  100 ng/ml 0,1-0,2 μl 
 
 
The hybridization mix was heated at 95°C for 2 min and chilled on ice until 
use. The slides are incubated with 100 μl of hybridization mix and covered 
with slide-size cut parafilm. The slides were put on a grid into a plastic box 
with paper soaked with 5xSSC, 40% formamide and incubated over-night at 
55°C. On the following day all solutions should be sterile but not necessarily 
to be RNase free. The solutions for all 37°C and 60°C washing steps should 
be pre-warmed.  
 
NTE SSC / formamide Maleic acid solution 
0,5 M NaCl 
10 mM Tris pH 7,0 
5 mM EDTA 
0,5x SSC 
20% formamide 
11,61g of maleic acid  
dissolve in 800ml H2O 
+ 30 ml NaCl(10M) 
adjust pH to 7.5 with NaOH 
10M 
adjust to 1l  
 
prewarm to  37°C prewarm to 60°C  
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All room temperature washes are performed on a shaker. The parafilm was 
floated off with 5x SSC at RT. The sections were washed three times for 20 
min in the same solution. In 0,5x SSC and 20% formamide the sections were 
washed at 60°C for 40 min. The solution was changed and placed at room 
temperature to cool down. Then the slides were equilibrated in NTE solution 
at 37°C for 15 min. Afterwards a second NTE wash for 30 min at 37°C with 10 
μg/ml RNase, to remove the unspecific riboprobe binding. After a washing 
step for 15 min at 37°C in NTE, and 0,5x SSC and 20% formamide for 30 min 
at 60°C, finally the sections were washed in 2x SSC for 30 min at room 
temperature.  
The slides were incubated with a 1x blocking solution diluted in maleic acid/ 
NaCl solution. The antibody against digoxigenin conjugated with alkaline 
phosphatase is diluted 1:200 in blocking solution and the sections incubated 
over-night at 4 °C (again covered with slide-size cut parafilm). 
The third day started with the removal of parafilm with 1xTBS.  
 
10xTBS Tween /levamisole 
80g NaCl 
2g KCl 
250ml 1M Tris/HCl pH 7,5 
add H2O to 1 liter 
0,1% Tween-10 
0,5 mg/ml levamisole 
 
 
The slides were washed four times for 10 min and once for 20 min in TBS. 
Next step was to rinse them in 1x Tween/ Levamisol solution for 10 min. BM 
purple substrate (Roche) was added with Tween/ Levamisole 1x solution, in 
order to reduce the activity of endogenous phosphatases. The slides were 
stained in the dark.  Afterwards slides were rinsed for 10 min in PBS with 
1mM EDTA to stop the reaction. The sections were mounted with Kaiser`s 
glycerol gelatine. 
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5.7 Protein analysis  
5.7.1 Preparation of vibratome sections 
The adult mice were sacrificed by asphyxiation with CO2 and the brains were 
dissected. The brains were fixed in 50ml cold 4% PFA, gently shake for 48h at 
4°C. After this incubation, the brains were stored in 0.4% PFA at 4°C until 
use. Coronal sections with a thickness of 50µm were produced using a 
vibratome (Microm). The floating sections were stored in 0.4% PFA at 4°C.  
 
5.7.2 Preparation of embryos for paraffin sections 
The adult mice were sacrificed by asphyxiation with CO2 and the brains were 
dissected. The embryos were fixed in 50ml cold 4% PFA, gently shake 
overnight at 4°C. The following day the brains were washed two times for one 
hour with saline solution (0,83% NaCl solution), then treated with a washing 
solution containing a mix of saline solution and EtOH 95% with the ratio of 1:1, 
for one hour and finally washed with EtOH 70% two times for 60 min. All 
washing steps were done at RT.  Afterwards the samples could be stored at 
4°C for a longer period or further processed to paraffin embedding. We left the 
tissue at least over-night in 70% EtOH. Then they were washed with an EtOH-
series (85%, 90% and 100%) each one half an hour and at RT. After the 
washing steps the solution (100% EtOH) was changed and the samples were 
placed over-night in 100% EtOH at 4°C, gently shaken. Next day: Tissue were 
transferred into xylene, washed two times for 1 hour (gently shaken at RT), 
then incubated with a mix of xylene and paraffin (ratio 1:1) for 1 hour at 60°C 
using a Tissue Tek Thermal console and Dispensing console (Miles 
Scientific). As embedding material “Gewebeeinbettungsmaterial Vogel-Histo 
Comp” (Vogel) was used. Three further steps with paraffin for 60 min at 60°C 
followed. Then the tissue was ready to be oriented and embedded in a 
paraffin block (using peel-a-way disposable plastic tissue embedding moulds 
from Polyscience, Inc.). The paraffin blocks were stored at 4°C until further 
use. For sections, a microtome 2035 from Leica Instruments was used. The 
paraffin block was fixed to the microtome and sections were cut with a 
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thickness of 7 μm. In order to flatten the sections, they were transfered in a 
histobath (HI1210, Leica Instruments). During the incubation (floating in water 
at 40°C for 10 min) the sections become more flat, scratches are removed 
and the tissue distended. The sections were collected on Superfrost slides, 
dried over-night at 37°C and then stored at RT. 
 
5.7.3 Preparation of tissue for cryosections 
The adult mice were sacrificed by asphyxiation with CO2 and the brains were 
dissected. The brains were fixed in 50ml cold 30% sucrose/PBS. Then the 
embryos were rinsed in PBS, embedded in OCT Tissue Tek (Sakura Finetek, 
Netherlands), frozen in dry ice and stored at –80°C. 
For frozen sections a cryostat CM 3050 from Leica Instruments was used. 
Samples were fixed to the object with Tissue Tek. The object temperature and 
the chamber temperature of the cryostat were set to –20°C. The thickness of 
the sections was 20μm. Continuous cutting mode with 30-60% speed was 
used. The sections were collected on Superfrost slides (Fisher Scientific, 
USA) and stored at –20°C. 
 
 
5.8 Immunohistochemistry 
5.8.1 Immunohistochemistry using paraffin sections 
Paraffin sections were de-paraffinized 3x for 10min in xylene and hydrated 
through a decreasing ethanol gradient 2x5min EtOHabs, 2x5min 95% EtOH, 
2x5min 70% EtOH and 1x10min PBS. The antigen retrieval was performed by 
microwave treatment (3min 800W, 8min360W) in 1x Antigen Retrieval Citra 
buffer (Biogentex). The cooled sections were rinsed 3x in H2Odd and 3x in 
PBS. Afterwards the endogenous peroxidase activity was blocked by 10min 
incubation in 5% H2O2 diluted in PBS/MetOH (1:1) at RT followed by washing 
in PBS. Sections were rinsed 3x5min in PBS, circled with Pap-Pen (Beckman 
Coulter) and incubated for 30min with blocking solution (5% normal swine 
serum; DAKO in PBS) in a humid chamber. Incubation with the first antibody 
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was performed at 4°C O/N. Sections were rinsed next day 3x10min in PBS 
and afterwards incubated for 30 min with the appropriate biotinylated 
secondary antibody (Vector). After 3x10min rinsing in PBS, 30min incubation 
with the VECTSTAIN ABC system was performed according to the instruction 
of the manufacturer (streptavidin-biotin-complex coupled with horse radish 
peroxidase; Vector Laboratories). The sections were stained with 3,3-
diaminobenzidine (DAB, Sigma) dissolved in H2O. Replacing the DAB with tab 
water stopped the reaction, the sections were dehydrated by an increasing 
ethanol gradient (H2Odd, 70% EtOH, 95% EtOH and EtOHabs) followed by 
incubation in xylene and mounted with Eukitt (O.Kindler). 
 
Following primary antibodies were used: 
Cre   1:2000 
TH   1:500 
B23   1:2000 
p53   1:1000 
8-oxoguanine 1:200 
Neuroketals  1:1000 
NITT   1:1000 
Parkin   1:500 
Ubiquitin  1:3000 
Synphilin  1:500 
α-synuclein  1:5000 
 
 
5.8.2 Immunohistochemistry using vibratome sections 
Free floating vibratome sections were transferred into a 48 well plate 
containing PBS and endogenous peroxidase activity was blocked by 15 min 
incubation in 1% H2O2 diluted in PBS/MetOH (1:1). Subsequently, sections 
were rinsed 3x 10min in PBST followed by 30min incubation in 5% NSS/PBST 
to block unspecific binding sites. Incubation with the first antibody, 
appropriately diluted in 5% NSS/PBST, was performed O/N at 4°C. After 
rinsing 3x15 min in PBST the sections were incubated for 30 min at RT with 
the adequate biotinylated secondary antibody (Vector) and rinsed again 3x15 
min with PBST. 30min incubation with the VECTASTAIN ABC system was 
performed according to the instruction of the manufacturer (streptavidin-biotin-
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complex coupled with horse radish peroxidase; Vector). Sections were finally 
rinsed 2x15min with PBST and 2x15min with PBS. The sections were stained 
with either 3,3-diaminobenzidine (DAB;Sigma) or with Histogreen (Vector). 
The reaction was stopped with tap water onto uncoated glass slides. Sections 
were dried for 1 hr at RT, shortly dipped into xylene and mounted with Eukitt 
(O. Kindler)  
 
Following primary antibodies were used: 
Cre 1:3000 
TH 1:2000 
B23 1:2000 
 
 
5.8.3 Immunoflorescence using paraffin sections 
Paraffin sections were de-paraffinized 3x for 10 min in xylene and hydrated 
through a decreasing ethanol gradient 2x5 min EtOHabs, 2x5 min 95% EtOH, 
2x5 min 70% EtOH and 1x10 min PBS. The antigen retrieval was performed 
by microwave treatment (3 min 800W, 8 min 360W) in 1x Antigen Retrieval 
Citra buffer (Biogentex). The cooled sections were rinsed 3x in H2Odd and 3x 
in PBS. Sections were rinsed 3x5 min in PBS, circled with Pap-Pen (Beckman 
Coulter) and incubated for 30 min with blocking solution (5% normal swine 
serum; DAKO in PBS) in a humid chamber. Incubation with the first antibody 
was performed at 4°C O/N. Sections were rinsed next day 3x10 min in PBS 
and afterwards incubated for 30 min with the appropriate fluorescent 
secondary antibody (Molecular Probes). After 3x10 min rinsing in PBS section 
were mounted with Vectashield mounting material (with or without DAPI).  
 
Following primary antibodies were used: 
TH  1:200 
Cre  1:200 
B23  1:200 
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5.8.4 COX staining using cryosections 
The sections were dried for 20-30 min at RT. After rinsing with PBS dections 
were stained using cresylviolett for max. 1 min. Sections were rinsed with 
PBS, followed by 10 min incubation in COX buffer at RT (gently shaking). 
Sections were stained using COX reaction mix for 30-40 min at 37°C. 
Reaction was stopped by rinsing the sections 3x for 3min with COX buffer. 
Sections were dehydrated in an increasing ethanol gradient (H2Odd, 70% 
EtOH, 95% EtOH and EtOHabs) followed by incubation in xylene and mounted 
with Eukitt (O. Kindler). 
 
COX buffer 
50mM sodium phosphate pH 7.2  
200mg/ml sucrose 
 
COX reaction mix 
50mM sodium phosphate pH 7.2 
10mg/ml cytochrome c 
10mg/ml DAB 
200mg/ml sucrose 
catalase 1.600U/ml 
 
5.8.5 Hematoxylen/eosin staining of paraffin sections 
For hemaloxylen/eosin staining, paraffin sections with a thickness of 4µm 
were deparaffinized 2x for 5min in xylene and hydrated through a decreasing 
ethanol gradient (2x3min EtOHabs, 2x3min 95%EtOH, 2x3min 70%EtOH and 
3min tap water) followed by 5min incubation in Mayers hemalaun (Applichem), 
1min in 0.5% HCl in 70%EtOH and 5min treatment with running tap water to 
differentiate the signal. Sections were counter-stained for 1min with eosin 
(Sigma), washed in H2Odd and dehydrated through an increasing ethanol 
gradient (H2Odd, 3min 80%EtOH and 2x2min EtOHabs). After 2x5min 
incubation in xylene, the sections were mounted with Eukitt (O.Kindler). 
 
Eosin staining solution 
30ml  1% Eosin 
270ml  70%EtOH 
3ml  glacial acetic acid 
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5.8.6 ß-galactosidase staining 
For β-galactosidase whole mount staining, dissected brains were cut with a 
razor blade in the appropriate planes. The organs were rinsed 3x for 10min 
with washing buffer and subsequently stained with X-gal staining solution at 
37°C over night. After the staining, slices were postfixed with 4% 
paraformaldehyde at 4°C over night and kept in 1xPBS at 4°C for analysis. 
For β-galactosidase staining of cryosections, dissected brains were frozen in 
O.C.T. compound (Tissue Tek, Sakura Finetek) on ethanol/dry ice and 10µm 
sagital cryosections were prepared (cryostat – Leica). Sections were fixed for 
10min in 4% paraformaldehyde and β-galactosidase staining was performed 
as described for whole mount samples. Afterwards, sections were 
counterstained with nuclear fast red (Sigma) and mounted with Eukitt 
(O.Kindler).  
 
washing buffer 
5mM   EGTA 
2mM   MgCl2 
0.01%  sodium-deoxycholat 
0.02%  NP-40 
solved in PBS 
 
X-gal staining solution 
5mM   EGTA, pH8 
2mM   MgCl2 
0.01%  sodium-deoxycholat 
0.02%  NP-40 
10mM  K3[Fe(CN)6] 
10mM  K4[Fe(CN)6] 
0.5mg/ml X-gal (50mg/ml in dimethylformamide; Applichem) solved 
in PBS 
 
5.8.7 HPLC-Electrochemical Detection 
For measurements of dopamine release, control and mutant mice were 
sacrificed at P40, the striata were frozen in liquid nitrogen. After weighing, the 
tissue was homogenized in 300µl 20mM sodium acetate buffer with 0,1% 
Trition-X-100. An aliquot was processed for analysis of dopamine. An 100µl 
aliquot was added to 900µl of 0,1M sodium acetate buffer containing 1% 
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Trition-X-100, 25mM ethylenediaminotetraacetic acid (EDTA) and as internal 
standard N-methyl-dopamine. Following deproteinization with 50µl HClO4 
(70%) and centrifugation. 100µl of the supernatant were processed by 
alumina extraction in triplicate. Dopamine was detected by HPLC-ED (µ-
Bondapack-C18 column, 10µm particle size, Waters system with pump 510; 
sample processor 740; Metrohom amperometric detector with glassy carbon 
electrodes at a potential of 0.72V against an Ag/AgCl reference electrode) and 
quantified by comparison to the internal standard. Elution was performed with 
50mM HClO4 containing 25mM EDTA at a flow rate of 1-1,2ml/min. 
Homogenates were processed for dopamine determination by HPLC-ED as 
described (Otto and Unsicker, 1990). 
 
5.8.8 Quantitative analysis of dopaminergic neurons  
Total numbers of TH positive neurons in SN and VTA, identified according to 
established anatomical landmarks, were counted on more than 20 sections 
per animal, immunostained with TH antibody. In the case of double 
immunohistochemistry every 4th section was used for cell counting spanning 
the entire region containing dopaminergic neurons. For each experimental 
group at least 3 mice were used. The ImageJ program 
(http://rsb.info.nih.gov/ij/) was used to determine the optical density of TH 
signal in the striata of control and mutant mice. Statistical analysis was 
performed by using the GraphPad Prism program (GraphPad, USA). 
Statistical significance was assessed by Students t-test,  one-way ANOVA or 
two-way ANOVA. P values are expressed in comparison to respective control 
(*, p<0.05; **, p<0.01; ***, p<0.001).   
 
 
 
 
 
 77
  Materials and methods 
   
  
5.9 Mouse work 
5.9.1 C57/Bl6 
This strain is bred by Charles River Laboratories (Wilmington, USA). These 
mice were used to backcross the generated transgenic lines. Mice are kept in 
a pathogen-free facility with a 12 hours light-dark cycle and water/food ad 
libitum 
 
5.9.2 Tamoxifen treatment 
Tamoxifen (Sigma) was dissolved in sunflower seed oil/ethanol (10:1) mixture 
at a final concentration of 10mg/ml. Eight weeks old mice were injected 
intraperitoneally with 1mg of tamoxifen twice a day for 5 consecutive days. 
Vehicle-treated animals were injected with 100µl of sunflower seed oil/ethanol 
mixture.  
Tamoxifen: 50mg tamoxifen (Sigma) was added to 500µl EtOHabs plus 4,5ml 
sunflower seed oil (Sigma) and dissolved under slow rotation for about 2hrs at 
RT. After tamoxifen solved it was stored at 4°C for up to three days.  
 
5.9.3 MPTP 
Adult mice received 3 intraperitoneal injections of 30mg/kg MPTP 
hydrochloride (Sigma) dissolved in 0,5ml of 0,9% saline adjusted to pH 7,4 at 
24hrs intervals. In the case of the TIF-IADATCreERT2 mice the first injection was 
given 2 weeks after the tamoxifen treatment. Control mice received injections 
of saline according to the same protocol (Schober, et al., 2007). 
 
5.9.4 Treatment with L-DOPA 
Treatment of mice with L-DOPA was performed as described (Szczypka, et 
al., 2001). Mice were weighed daily, and afterwards injected with L-DOPA 
(50mg/kg) consisting of 1,5mg/ml L-DOPA dissolved in 2,5mg/ml ascorbic 
acid. In addition liquid food, which is easier accessible, was provided.  
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5.9.5 Implantation of dopamine pellets 
Pellets, containing a biodegradable matrix, that effectively and continuously 
releases dopamine (1mg/day) for 30 days (Innovated Research of America), 
were implanted subcutaneously in the animal.  
 
5.9.6 Behavioral assessment 
One week before the experimental period, mutant and control male mice were 
transferred to standard single mouse cages. All results are represented as 
mean +/- SEM. The genotype effect was analyzed using unpaired two-tailed 
Student’s t test or two-way ANOVA using the Prism computer program.  
 
5.9.7 Rotarod 
Motor coordination measurements were done on the rotating drum with 
accelerated speed (Accelerator: Rotarod, Jones & Roberts, for mice 7650, 
TSE). After 10min adaptation at 2,5 rpm, the time the animal spent on the 
accelerating rod was recorded. 
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7. Abbreviations  
 
 
ERT2   LBD of the estrogen receptor harboring 2 pointmutations 
EtOH  ethanol 
h   hour 
H2O  water 
H2O2  hydrogen peroxide 
HCl  hydrochloric acid  
Hsp  heatshock protein 
 
IHC  immunohistochemistry 
i.p.   intraperitoneal 
 
kb   kilo base pair 
Kferric   potassium hexacyanoferrat(II)trihydrate 
Kferroc  potassium hexacyanferrat(III) 
 
l   liter 
LacZ  ß-galactosidase gene 
LBD  ligand-binding domain 
LoxP  Cre recombinase recognition site 
 
 
µ   micro (10-6) 
M   molar 
mg   milligram 
min  minute 
ml   milliliter 
mM  millimolar 
mRNA  messenger- ribonucleic acid 
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n   nano (10-9) 
NaCl  sodium chloride 
NaOH  sodium hydroxide 
NID  non-ionic detergent buffer 
NP40  nonidet P40 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PFA  paraformaldehyde 
pH   pH-value 
 
RNA  ribonucleic acid 
RNase   ribonuclease 
rpm  rounds per minute 
RT   room temperature 
 
s   second 
SDS  sodiumdodecylsulfate 
 
TAE  tris acetate EDTA buffer 
TBE  tris borate EDTA buffer 
TE   tris EDTA 
TH   tyrosine hydroxylase 
 
wt   wildtype 
 
X-gal   5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside
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